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ABSTRACT
Acute mountain sickness (AMS) is a common problem while ascending at high 
altitude. AMS may progress rapidly with fatal results if the acclimatization process 
fails or symptoms are neglected and the ascent continues. It affects 25% of those 
ascending to altitudes of 1850 to 2750 m, 42% at altitudes of 3000 m, and even 84% 
of those attempting a tourist flight to Lhasa, Tibet (3860 m). The most common 
reason for altitude illness is a too rapid ascent. There is a need for a non-invasive, 
specific, and convenient field method for the detection of inadequate acclimatization 
and impending AMS. Arterial oxygen saturation (SpO
2
) measurement is useful in 
anticipating AMS, but it is susceptible to many disruptive factors in the field (for 
example temperature). Autonomic cardiac response to increasing altitude could 
be a low-cost non-invasive test to predict impending AMS, in addition to helping 
distinguish those who are at risk for AMS and those who are acclimatizing well.
The purpose of the present study was to: 1. assess the prevalence of the symptoms 
and signs of acute mountain sickness among Finnish travelers climbing Mount 
Kilimanjaro, Tanzania; 2. investigate if post-exercise oxygen saturation (Ex-SpO2) 
at high altitudes predicts AMS better than arterial O
2
 saturation at rest (R-SpO
2
) or 
resting heart rate (HR) alone; 3. evaluate if heart rate variation (HRV) level or HRV 
changes have a relationship to AMS during ascent and provide new information on 
the deterioration of cardiac autonomic function as measured by HRV, not only at 
altitudes between 2400 and 5000 m, which are most frequent among climbers, but 
also at extreme altitudes above 5000 m in field conditions; 4. generate tools for AMS 
for non-medical persons to estimate the risk in field conditions; and 5. describe a 
typical AMS case and the difficulties to treat AMS at field conditions. The data was 
collected during several treks to Kilimanjaro and climbing expeditions to Denali, 
Shisha Pangma, Ulugh Muztagh, Island Peak, and Mount Everest 2001-2009. 
 The incidence of AMS was very high (75%) for the trekkers at Mt Kilimanjaro. 
In climbing expeditions, subjects susceptible to AMS had lower SpO
2
 at rest 
and especially during exercise before the clinical manifestations of AMS so daily 
measurements of SpO
2
 were taken at these times to best predict the subsequent 
AMS at higher altitude if ascending continued. Subjects susceptible to AMS had 
lower root mean square successive differences and high-frequency power of HRV 
before the clinical manifestations of AMS than those who acclimatized well and did 
not get AMS 2-5 days later if ascending continued.
The treatment of AMS in the field is difficult and time consuming, where 
possibilities for medical treatment and oxygen substitution might be limited. 
Prevention is the safest and the most efficient method of care. Realising the risk of 
mountain sickness, active inquiry about symptoms and correctly timed reaction to 
them, in other words interrupting the ascent or descending, helps to reduce, and 
even to prevent, the development of serious problems.
5TIIVISTELMÄ
Vuoristotauti (AMS) on yleinen ongelma, kun noustaan yli 2500 m korkeuteen. 
AMS voi edetä nopeasti henkeä uhkaavaksi, jos sopeutuminen vallitsevaan kor-
keuteen epäonnistuu tai oireet ovat jääneet huomioimatta ja nousu jatkuu. Sai-
rastuvuus on n. 25 % 1850–2750 m korkeudessa ja 42 % 3000 m korkeudessa. 
Lhasaan (3860 m), Tiibetiin lentäen matkustavista jopa 84 % sairastuu. Tavallisin 
syy AMS:n on liian nopea nousu. Vuoristotaudin diagnoosi on oireperusteinen 
ja tarve ei-kajoaviin, kenttäoloissakin toimiviin mittausmenetelmiin taudin 
tunnistamiseksi ja ennakoimiseksi on ilmeinen. Veren happisaturaation (SpO
2
) 
mittaus auttaa AMS:n ennakoimisessa mutta se on altis monille häiriötekijöille 
(esim. lämpötila). Autonomisen hermoston sydänvasteiden kuten sydämen sy-
kevaihtelun (HRV) muutosten on arveltu olevan edullinen ei-kajoava menetelmä 
ennakoida AMS.
Tämän tutkimuksen tavoitteena oli 1. arvioida AMS:n esiintyvyyttä suoma-
laisilla matkailijoilla Kilimanjarolla; 2. selvittää onko rasituksen jälkeinen SpO
2
 
parempi ennustamaan kehittyvää AMS:a kuin lepo SpO
2
 tai leposyke (HR) yk-
sinään; 3. tutkia HRV:n ja AMS:n välistä yhteyttä ja tuottaa uutta tietoa HRV 
muutoksista tavanomaisten kiipeilykorkeuksien (2400–5000 m) lisäksi äärim-
mäisissä korkeuksissa (> 5000 m); 4. tuottaa AMS riskin arviointiin työkaluja 
myös maallikoiden käyttöön sekä 5. kuvata tyypillinen AMS potilastapaus sekä 
sen hoitoa kenttäolosuhteissa. Tutkimusaineisto koottiin kyselytutkimuksena 
Kilimanjarolla sekä kenttämittauksin Denali, Shisha Pangma, Ulugh Muztagh, 
Island Peak ja Mount Everest retkikuntien aikana 2001–2009.
Tutkimuksen perusteella AMS:n esiintyvyys suomalaismatkailijoilla Kiliman-
jarolla oli erittäin korkea (75 %). Ylävuoristokiipeilyretkikunnissa AMS:lle alttii-
den kiipeilijöiden lepo- ja erityisesti rasituksen jälkeinen SpO
2
 laski merkittävästi 
ennen AMS:n kliinisten oireiden ilmaantumista. Samoin HRV:n RMSSD ja HF 
komponenttien lasku 2400 m korkeudessa ennakoi AMS:n kehittymistä ylem-
pänä 2-5 vuorokautta myöhemmin, mikäli nousua jatkettiin ilman lepopäiviä.
Vuoristotaudin hoito kenttäolosuhteissa on vaikeaa ja aikaa vievää. Ennalta-
ehkäisy on turvallisin ja tehokkain menetelmä AMS:n hoidossa sillä lääkehoidon 
mahdollisuudet ovat rajalliset ja olosuhteista riippuen potilaan evakuoiminen 
alas voi olla mahdotonta. Päivittäiset lepo- ja rasitus-SpO
2
 sekä HRV mittaukset 
voivat auttaa erottamaan hyvin sopeutuvat kiipeilijät niistä, joille myöhemmin 
voi tulla AMS korkeammalla. Vuoristotaudin riskin tiedostaminen, oireiden ak-
tiivinen seuraaminen ja oikea-aikainen reagointi niihin, eli nousun keskeyttä-
minen tai laskeutuminen, voi estää myöhempien vakavien ja henkeä uhkaavien 
ongelmien kehittymisen.
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REVIEW OF THE LITERATURE
1. INTRODUCTION 
According to the World Health Organization (WHO) statistics, around 140 million 
people live permanently at altitudes higher than 2500 m (WHO 1996). The number 
of lowland dwellers travelling to altitude for work (soldiers, miners, construction 
workers, and astronomers), for seeking adventure or recreation (skiing, trekking, 
and climbing) at high altitudes has greatly increased in recent decades. Acute altitude 
illnesses are potentially serious conditions that can affect otherwise healthy and fit 
individuals who ascend too rapidly to altitude. They include high altitude headache 
(HAH), acute mountain sickness (AMS), high altitude cerebral oedema (HACE), 
high altitude pulmonary oedema (HAPE) (Imray et al. 2011), high altitude cough 
syndrome (Khumbu cough) (Litch and Tuggy 1998), high altitude retinopathy 
(Butler et al. 1992), and transient neurological disorder at high altitude (Cauchy 
et al. 2002) or high altitude global amnesia (Litch and Bishop 1999, Litch and 
Bishop 2000).
Health care practitioners may be involved in expeditions themselves, but the 
awareness of potential altitude related problems is important even for healthcare 
practitioners working at lower altitude, as patients may ask for advice regarding 
the safety of a proposed journey and how to prevent illness at altitude (Imray et al. 
2011). The most important of the acute altitude illnesses are AMS, HAPE, and HACE.
The ascent to the altitude requires adaptation and acclimatisation to both lower 
air pressure and diminished partial pressure of oxygen (Hackett and Roach 2001). 
If the adaptation process fails due to too rapid an ascent rate or to the exceptional 
characteristics of the climber, one or more altitude related illnesses may result. 
AMS is the most common of these problems.
If those at risk of AMS could be detected more efficiently than is currently 
possible, prophylactic medicine like acetazolamide could be used, or the ascent 
rate of the whole expedition could be optimized to avoid the risk of changing the 
climbing expedition into a rescue mission.
14
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2. ALTITUDE RELATED ILLNESSES 
2.1. DEFINITION OF HIGH ALTITUDE 
High altitudes can be defined as following (Imray et al. 2011):
- Intermediate Altitude 1500-2500 m 
- High Altitude: 2500-3500 m 
- Very High Altitude: 3500-5500 (5800) m 
- Extreme Altitude: above 5500 (5800) m
- “Death Zone”: above 8000 m
Each of these has different associations with physiological changes. At 
intermediate altitude the first signs of physiological changes are detectable. Arterial 
oxygen saturation may be above 90% and altitude illnesses are rare but possible 
with rapid ascent, exercise, and susceptible individuals. Altitude illness is common 
at high altitude when individuals ascend rapidly, and it is more common at very 
high altitude. Arterial oxygen saturation may be below 90% and marked hypoxemia 
occurs during exercise. The highest permanently inhabited town in the world at the 
present time appears to be La Rinconada, a mining village of over 7000 people in 
southern Peru at an altitude of up to 5100 m (West 2002). Subjects present marked 
hypoxemia at rest at these extreme altitudes. There is progressive deterioration, 
despite maximal acclimatisation, and permanent survival is not thought to be 
possible (Imray et al. 2011). The term “death zone” was originally coined in a book 
published in 1952, “The Mountain World” by Swiss doctor Edouard Wyss-Dunant, 
and this point is generally tagged as 8000 m where the atmospheric pressure 
is less than 356 millibars (Darack 2001). Before the entering the “Death zone”, 
prolonged acclimatisation (> 6 weeks) is essential. Most mountaineers require 
supplementary oxygen to climb safely. Arterial oxygen saturations may vary from 
48 to 55% (measurement done by Finnish Everest expedition at the summit of Mt 
Everest 2009). Rapid deterioration is inevitable and time spent above this altitude 
is strictly limited. (Imray et al. 2011).
2.2. NORMAL ACCLIMATIZATION
Acclimatization is the process by which the body adapts to the decreased availability 
of oxygen at high altitudes and adequate acclimatisation is essential for safe 
travelling in the mountains. It includes a number of physiological changes that 
occur over a variable time course (Figure 1). The most important are respiratory and 
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haematological changes (Moore et al. 1998). Some changes take place within minutes 
while others take several weeks. At intermediate to high altitudes, a significant 
degree of acclimatisation takes place over two to four days, but the adjustment 
process can take more days or even weeks depending on the altitude. 
Figure 1. Time course of physiological adaptations to altitude. Time course of acclimatisation and adaptive 
changes plotted on log time scale. The curve of each response denotes the rate of change. 
(Adapted from Imray et al. 2011, originally Peacock 1998).
Ventilation rapidly increases with acute hypoxic exposure, and this hypoxic 
ventilatory response (HVR) was evident even after 56 or 62 days (Steinacker et 
al. 1996, Savourey et al. 1996) of chronic exposure from a Himalayan expedition. 
An enhanced HVR is generally presumed to enable better performance at altitude 
by maintaining arterial oxygen saturation levels (Schoene et al. 1984, Masuyama 
et al. 1986). Another common adaptation with chronic hypoxic exposure is an 
elevation in erythropoiesis and total haemoglobin mass (Pugh 1964), enabling 
greater oxygen delivery to the body for a given cardiac output (Gunga et al. 2007). 
Normal acclimatization also includes the rise of the sympathetic activity of the 
muscles (Mazzeo et al. 1995), increased urine excretion, changes in breathing rhythm 
during sleeping (Cheyne-Stokes – type breathing), nightly wakings and the change 
of sleep to abstract and strange, and subject may have dyspnoea (Ward et al. 1995). 
Cerebral artery dilatation due to hypoxia maintains cerebral oxygenation at extreme 
altitude and in acute hypoxia and this supposed to cause headache (Wilson et al. 
2011). The decreased partial pressure of oxygen (PO
2
) starts acclimatization and, 
as a consequence, the RR increases to improve the PO
2
. At the same time, the 
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partial pressure of arterial carbon dioxide (PaCO
2
) becomes smaller. This respiratory 
alkalosis will usually be balanced within an hour with urine excretion and bicarbonate 
secretion (Rodway et al. 2003), which takes place in the kidneys and has increased 
over the first 24–48 hours at altitude. The exact reason for the increase in urine 
excretion is unknown, but is believed to be important for acclimatization when the 
electrolyte balance changes when ascending high altitude (Basnyat and Murdoch 
2003, Cumbo et al. 2002). This is why ascent to altitude often results in dehydration, 
also owing to exercise, hyperventilation, and limited access to water. It is important 
to drink plenty of fluids during acclimatization so that the sufficient diuresis will be 
maintained (Barry and Pollard 2003). Dehydration leads to the decrease in urine 
excretion and increased risk to experience acute mountain sickness. In published 
case studies, weakening diuresis and ketosis have been connected to serious AMS. 
Patients have been dehydrated due to an inadequate fluid intake and diuresis has 
not started leading to fluid accumulation in the tissues (for example Bärtsch et 
al.1991, Karinen and Tikkanen 2005). Although an association between AMS and 
dehydration has been noted (Basnyat et al. 2001), it is unclear whether dehydration 
is an independent risk factor for AMS. Acclimatization to the new altitude begins 
immediately but the symptoms of mountain sickness will usually develop in a 6–12 
hour window after arriving at the new altitude. Development of serious mountain 
sickness usually takes 12–48 hours, but some serious anticipating symptoms can 
also be evident earlier (Hackett and Roach 2001, Basnyat and Murdoch 2003). 
If an ascent rate to the new altitude is fast, and the compensation mechanisms 
weakened, symptoms can begin even within an hour (Hackett and Roach 2001). 
The rate of acclimatisation varies between individuals and takes at least 2 days 
without symptoms after the arrival to the new altitude (Barry and Pollard 2003). 
The most important risk factors for the development of high-altitude illness are 
rate of ascent, altitude reached (especially the sleeping altitude), and individual 
susceptibility (Basnyat and Murdoch 2003).
2.3. ALTITUDE ILLNESSES
Altitude related illnesses can be both acute and chronic (Rupert and Koehle 2006). 
Acute altitude related illnesses includes high altitude headache (HAH), acute 
mountain sickness (AMS), high altitude cerebral oedema (HACE), high altitude 
pulmonary oedema (HAPE) (Imray et al. 2011), high altitude cough syndrome 
(Khumbu cough) (Litch and Tuggy 1998), high altitude retinopathy (Butler et al. 
1992), and transient neurological disorder at high altitude (Cauchy et al. 2002) 
or high altitude global amnesia (Litch and Bishop 1999, Litch and Bishop 2000).
Subacute mountain sickness, sometimes called high altitude pulmonary 
hypertension, is a subacute or chronic condition. It yields persistent pulmonary 
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hypertension, leading to right heart failure, dyspnoea, oedema/anasarca, ascites, 
and hepatomegaly. There are adult and infantile subtypes that are often associated 
with chronic mountain sickness (León-Velarde et al. 2005).
In chronic mountain sickness (Monge´s disease, chronic soroche), patients 
typically have polycythaemia and pulmonary hypertension leading to right heart 
failure. Symptoms include headaches, insomnia, lethargy, dizziness, tinnitus, 
plethora, polycythaemia, and bone and muscle pain (Hackett and Roach 2004, 
Reeves and León-Velarde 2004). It affects native (including indigenous) populations 
and long-term residents living at altitudes exceeding 2500 m.
2.3.1. Prevalence and individual susceptibility 
AMS is a common problem at altitude. It affects 25% of those ascending to altitudes 
of 1850 to 2750 m (Honigman et al. 1993), 42% at altitudes of 3000 m (Hackett 
and Roach 2001), and even 84% of tourists flying direct to Lhasa (3860 m) without 
preacclimatization (Barry and Pollard 2003). In a prospective observational study, 
84% of people who flew to 3740 m developed acute mountain sickness (Murdoch 
1995), while about 50% of trekkers who walk to altitudes higher than 4000 m in 
the same region over five or more days got AMS. In the Himalayas in Nepal, the 
incidence of AMS has been reported to be 0% at 2500 to 3000 m, 10% at 3000 to 
4000 m, 15% at 4000 to 4500 m, 51% at 4500 to 5000 m, and 34% over 5000 m 
(Vardy et al. 2006). The prevalence of AMS depends on an individual’s susceptibility, 
the rate of ascent, and the absolute altitude achieved (especially the sleeping altitude) 
(Basnyat and Murdoch 2003). Speed of ascent, exercise during or immediately 
after ascent, male sex, and youth are all risk factors also (Barry and Pollard 2003).
HACE is said to be rare and usually occurs only at altitudes over 4000 m (Imray 
et al. 2011). The incidence of HACE is much lower than for AMS, with estimates in 
the range 0.1-4.0% (Basnyat and Murdoch 2003). In two observational field studies 
at altitudes from 3350 to 5000 m, 1.2-1.8% developed HACE (Singh et al. 1969, 
Hackett et al.1976). Among the Gosainkund pilgrims in the Nepalese Himalayas 
at 4300 m, the incidence of HACE has been reported to be 31% (Basnyat et al. 
2000b). Ataxia has been mentioned as an early sign of impending HACE, and 
its incidence at 4505 to 4779 m is 0.26% (Wu et al. 2006). HAPE usually occurs 
above 2500 m, but it has also been recognised at altitudes between 1500 m and 
2500 m (Gabry et al. 2003). The prevalence of HAPE depends on the degree of 
susceptibility, the rate of ascent, and the final altitude. Its incidence is 0.0001% 
at 2700 m, increasing to 2% at 4000 m (Barry and Pollard 2003). At an altitude 
of 4500 m, the prevalence may vary depending on the rate of ascent between 0.2 
and 6% in an unselected population (Bärtsch et al. 2002) and at 5500 m between 
2 and 15% (Bärtsch et al. 2005).
18
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An individual’s past performance at altitude is the main predictor of their 
future performance (Imray et al. 2011). Some people are more susceptible to AMS 
than others and variants of at least eight genetic polymorphisms show positive 
associations suggesting that acute mountain sickness is an environmentally 
mediated polygenic disorder. (Imray et al. 2011, MacInnis et al. 2011). Because of 
the polygenic nature of the human response to hypobaric hypoxia, several genetic 
loci, each with a small contribution, probably define the phenotype. These genes 
include the erythropoietin response gene, those that encode for nitric oxide synthase, 
and those that encode aldosterone synthase and angiotensin converting enzyme 
polymorphism (MacInnis et al. 2011).
The risk of developing acute mountain sickness was associated with better aerobic 
capacity, younger age, and higher body mass index (Gallagher and Hackett 2004). 
Obesity has been shown to be associated with the development of AMS, which may 
be partly related to greater nocturnal desaturation with altitude exposure (Ri-Li et 
al. 2003). Higher risk is also associated with living below 900 m altitude (Honigman 
et al.1993), ascent rate higher than recommendations, acquired altitude, sleeping 
altitude (Barry and Pollard 2003), and physical stress (Roach et al. 2000). Good 
aerobic capacity may increase risk if the person does not understand to proceed 
slowly and peacefully enough at the beginning of the ascent. In some studies, age 
has a slight protective effect (Silber et al. 2003, Moraga et al. 2008). Over 50-year-
olds have a smaller risk for AMS (Honigman et al.1993, Roach et al. 1995). The 
usual illnesses, such as asthma, diabetes, anemia, and arterial hypertension do 
not increase the risk (Peacock 1998). The more significant illnesses (for example 
coronary disease, all the premises that will elevate pulmonary hypertension at sea 
level, and chronic obstructive pulmonary disease, which weakens hemodynamic 
and respiration function, can increase the risk for AMS (Barry and Pollard 2003). 
No clinical feature or test has been shown to predict an individual’s susceptibility 
with any reliability (Imray et al. 2011). Arterial oxygen saturation determined 
20-30 minutes after exposure to simulated hypoxia, equivalent to that at 2300-
4200 m altitude, seems to be the best predictor of susceptibility (Burtscher et al. 
2008). Individuals who develop HAPE at altitudes of 4000 m show an abnormal 
increase in pulmonary artery pressure during brief or prolonged hypoxic exposure. 
Interestingly, they also have a greater pulmonary artery pressure rise during 
exercise in normoxia, pointing to a constitutionally generalized hyper reactivity of 
the pulmonary circulation. Furthermore, most HAPE-susceptible individuals have 
a low hypoxic ventilatory response, which leads to a low alveolar PO
2
 and thus 
a greater stimulus to hypoxic pulmonary vasoconstriction at any given altitude 
(Bärtsch et al. 2005).
The individual risk for AMS among healthy subjects can be estimates to be low in 
individuals with no prior history of altitude illness and when they are ascending no 
higher than 2800 m or individuals who are spending more than two days to arrive 
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at 2500-3000 m altitude with subsequent increases in sleeping altitude below 500 
m per day. The risk is moderate among: individuals with prior history of AMS and 
they are ascending to 2500-2800 m in one day; individuals that have no history 
of AMS and they are ascending to over 2800 m in one day; or individuals that are 
ascending more than 500 m per day (increase in sleeping elevation) at altitudes 
above 3000 m. The risk for AMS is high if: the subjects have a history of AMS and 
they are ascending to 2800 m or higher in one day; they have a prior history of 
HAPE or HACE; they are ascending to above 3500 m in one day or ascending more 
than 500 meter per day above 3500 m. The risk is very high at some mountains or 
routes where very rapid ascent profiles are common (e.g. Mt. Kilimanjaro) (Luks 
et al. 2010).
2.3.2. High altitude headache 
High altitude headache is defined by the International Headache Society as a 
headache that develops within 24 hours of ascent above 2500 m and resolves within 
8 hours of descent (Imray et al. 2011).
Headache is the most common and most prominent of the altitude related 
symptoms. A prospective observational study estimated that 80% of people who 
ascend to high altitudes are affected by high altitude headache (Wilson et al. 2009). 
Although high altitude headache, and AMS in general, share many characteristics 
with migraine, the responses of high altitude headache to the 5-hydroxytryptamine 
agonist sumatriptan have been inconsistent (Burtscher et al. 1995). Unlike a common 
migraine, high altitude headache resolves after 10-15 minutes of supplementary 
oxygen therapy (2 L per minute) (Imray et al. 2011).
High altitude headache is so common that it is quite often considered as a 
part of normal acclimatization. The headache often worsens during the night and 
with exertion. Most high altitude headaches resolve with mild analgesic treatment 
(paracetamol or ibuprofen). The person may need to stop the ascent or descend 
to lower altitude if the headache does not improve with simple analgesia (Imray 
et al. 2011).
2.3.3. Acute mountain sickness (AMS)
AMS is a non-specific syndrome characterized by the presence of headache and at 
least one of the following: gastrointestinal symptoms (like loss of appetite, nausea 
and vomiting), insomnia or difficulty sleeping, dizziness, and weakness or fatigue. 
It is a self-limiting syndrome, appearing 6-12 hours after arrival at high altitude 
and usually resolving in 1-3 days if properly treated (rest, descent to lower altitude, 
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medication etc.), but may sometimes progress to more serious, even life threating 
mountain sickness, such as HAPE and HACE (Imray et al. 2011). Headache is 
deemed the cardinal symptom, but the characteristics are not sufficiently distinctive 
to differentiate it from other causes of headache (Silber et al. 2003). The non-specific 
symptoms and signs of AMS can result in diagnostic confusion with other disorders, 
such as exhaustion, dehydration, hypothermia, alcohol hangover, and migraine. 
(Basnyat et al. 2000a). Many people who usually live at sea level are surprised on 
their first encounter with acute mountain sickness by debilitating tiredness, which 
may be compounded by sleeping difficulties. Individuals may note decreased urine 
output independent of fluid intake (Hackett and Rennie 1979). If the symptoms are 
ignored or diagnostic signs are absent, and the presence of abnormal neurological 
or respiratory signs can show progression to or development of HACE or HAPE 
(Basnyat and Murdoch 2003).
AMS and HACE have similarities in their pathophysiology (Hackett 1999, Roach 
and Hackett 2001, Bärtsch and Roach 2001). The exact mechanism causing these 
syndromes is unknown, although evidence points to a process in the central nervous 
system. The classic theory of the pathogenesis of high altitude headache has been that 
it results from increased intracranial pressure secondary to hypoxemia in people who 
have less compliant intracranial volumes (Roach and Hackett 2001). This theory is 
that AMS and the headache are a consequence of the circulation of the brain which 
has increased and as a consequence of which the capillary pressure increases, fluid 
trickles from the capillaries to the tissue, and the brain swells (Roach and Hackett 
2001, Basnyat and Murdoch 2003). Hypoxia causes both in the brain and the lungs 
hemodynamical and nervous reactions, which lead to the excessive perfusion of the 
capillary blood vessels, rise of capillary pressure, capillary leak, and finally oedema 
(Hackett and Roach 2001). Relative hypoventilation and impaired gas exchange 
(Moore et al.1986, Ge et al. 1997), increasing of the sympathetic activity (Bärtsch 
et al. 1991), and fluid retention and redistribution are typical (Swenson 1997) to 
the AMS cases. In moderate to severe AMS, raised intracranial pressure is typical 
(Basnyat and Murdoch 2003).
Several models have been created to explain the pathophysiology of AMS 
and HACE (Hackett and Roach 2001, Basnyat and Murdoch 2003, Wilson et al. 
2011). In Hackett and Roach’s model, hypoxemia elicits various neurohumoral and 
haemodynamic responses that ultimately lead to increased cerebral blood flow, 
altered permeability of the blood-brain barrier, and cerebral oedema. These changes 
result in brain swelling and raised intracranial pressure. According to the model, 
AMS occurs in people who have inadequate cerebrospinal capacity to buffer the brain 
swelling; those with a greater ratio of cranial cerebrospinal fluid to brain volume 
are better able to compensate for swelling through displacement of cerebrospinal 
fluid, and are less likely to develop AMS than people with a lower ratio.
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Basnyat and Murdoch presented (2003) that fluid accumulation in the brain 
may be caused by cytotoxic oedema (cell swelling due to increased intracellular 
osmolality), vasogenic oedema (leak of the blood-brain barrier with extravasation of 
proteins and fluid into the interstitial space), or both. In their model, the cytotoxic 
oedema with increased cerebrospinal-fluid pressure, decreased perfusion, and focal 
ischemia may occur in the later stages of HACE but it does not explain AMS or 
early HACE. 
The most accepted theory nowadays is that the oedema is vasogenic. The tissue 
will swell because of the capillary leak when extracellular fluid increases, which then 
will be followed by the cytotoxic oedema: in other words, the cells will swell from the 
growth of the intracellular pressure when the oxidation weakens. Changes consistent 
with vasogenic oedema are evident from HACE-patient MRI findings (Hackett et 
al. 1998). A vasogenic origin of oedema is alos supported by some animal tests 
(Krasney 1997) and the response to corticosteroids (Fishman 1975). Several factors, 
which cannot individually explain the process that triggers vasogenic oedema at 
high altitude include: raised cerebral capillary pressure resulting in a mechanical 
vascular leak; impaired cerebral autoregulation in the presence of hypoxic cerebral 
vasodilatation; and alteration in permeability of the blood-brain barrier because of 
hypoxia-induced chemical mediators such as bradykinin, histamine, nitric oxide, 
arachidonic acid, and vascular endothelial growth factor (Basnyat and Murdoch 
2003).
This classic theory of the pathogenesis of high altitude headache (that it results 
from increased intracranial pressure secondary to hypoxemia in people who have 
less compliant intracranial volumes (Roach and Hackett 2001)) has some problems. 
There does not appear to be a correlation between the headache of AMS and the 
presence of cerebral oedema (Bailey et al. 2006, Wilson et al. 2009) and retinal 
venous distension and the increased venous blood demonstrated by near infra-red 
spectroscopy, and more recently by MRI, imply that a relative venous insufficiency 
may exist in hypoxia. Slight increases in central venous pressure (e.g., from hypoxia-
induced pulmonary vasoconstriction) may further compromise venous outflow at 
altitude. Thus, the pathogenesis of headaches may currently be considered to be 
idiopathic (Wilson et al. 2011).
2.3.4. High altitude cerebral oedema (HACE)
Diagnosis of high altitude cerebral oedema (HACE) has been defined by the Lake 
Louise committee to include the symptoms of AMS plus gait ataxia or mental status 
changes, or both ataxia and mental status changes together, regardless of AMS 
symptoms (Roach et al. 1993). HACE is widely viewed as the end stage of AMS, and 
is normally preceded by symptoms of AMS. HACE is characterised by altered mental 
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status, including impaired mental capacity, ataxia, and altered consciousness, which 
may progress to coma and death due to brain herniation as soon as 24 hours after 
the onset of these symptoms. People with concomitant HAPE may progress very 
rapidly from AMS to HACE. Clinical examination may reveal papilledema, ataxia, 
retinal haemorrhages, and, occasionally, focal neurological deficits (Basnyat and 
Murdoch 2003, Imray et al. 2011). The proposed pathophysiology of AMS and 
HACE is presented in Figure 2.
Figure 2. Proposed pathophysiology of AMS and HACE. Adopted from Basnyat and Murdoch 2003, 
originally in Hackett and Roach 2001.
Portable hyperbaric chambers are effective for treating severe altitude illness 
(Luks et al. 2010), but they require constant tending by care providers and are 
difficult to use with claustrophobic or vomiting patients. Symptoms may recur when 
individuals are removed from the chamber (Luks et al. 2010). Use of a portable 
hyperbaric chamber should not delay descent in situations where descent is feasible.
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2.3.5. High altitude pulmonary oedema (HAPE)
High altitude pulmonary oedema manifests as a non-cardiogenic form of pulmonary 
oedema and is not necessarily preceded by acute mountain sickness (Imray et al 
2011). HAPE occurs most commonly one to five days after arrival at altitudes above 
2500 m and consists of dyspnoea with exercise, progressing to dyspnoea at rest, a 
dry cough, which then becomes productive with blood stained sputum, weakness, 
and poor exercise tolerance (Maggirorini 2010). As the disease worsens, severe 
dyspnoea and frank pulmonary oedema are obvious, with coma and death following 
if the condition is not treated. Physical findings may initially be subtle.
Early clinical signs include tachypnoea and tachycardia at rest as the illness 
progresses; fever is common, although rarely exceeding 38.3ºC. Crackles may be 
present on auscultation of the chest. HAPE is frequently accompanied by signs of 
HACE. There is no radiographic feature specific to HAPE and electrocardiography 
may show evidence of right-ventricular strain (Vock et al.1991, Basnyat and Murdoch 
2003).
HAPE may be overrepresented in men compared with women. People with 
abnormalities of the cardiopulmonary circulation that are associated with increased 
pulmonary blood-flow pressure, such as unilateral absence of a pulmonary artery 
or primary pulmonary hypertension, or both, are at increased risk of HAPE, even 
at moderate altitudes. Exercise and cold lead to increased pulmonary intravascular 
pressure, and may also be contributing factors to the development of HAPE (Basnyat 
and Murdoch 2003, Gallagher and Hackett 2004). Other risk factors include: high 
ascent rate or speed of ascent, exercise during or immediately after ascent, male 
sex, youth, and individual susceptibility (Barry and Pollard 2003).
Patients with high altitude pulmonary oedema tend to have lower oxygen 
saturations than unaffected people at the same altitude, but the degree of 
desaturation by itself is not a reliable sign of high altitude pulmonary oedema 
(Sartori et al. 2002). SpO
2
 among well acclimatized climbers is normally 80-86% at 
4200 m altitude but it can even be 75% for symptomless yet unacclimatized people: 
at less than 5500 m altitude, values below this are said to be diagnostic of HAPE. 
At 3500-5500 m, SpO
2
 is usually 50-60% for the HAPE patients (Peacock 1998).
The exact mechanism that causes HAPE is still unknown. It is established as the 
consequence of hypoxic pulmonary vasoconstriction and sufficient transmission of 
high pulmonary artery pressure and blood flow to portions of the pulmonary capillary 
bed, most likely due to regional unevenness in hypoxic pulmonary vasoconstriction 
(Bärtsch et al. 2005). Some characteristics of HAPE include: exaggerated pulmonary 
hypertension leading to vascular leakage through overperfusion, stress failure, 
or both (Basnyat and Murdoch 2003). There are several possible causes of the 
pulmonary hypertension seen in HAPE. The most widely accepted theory is that 
uneven hypoxic pulmonary vasoconstriction may cause regional overperfusion 
of capillaries in areas of least arterial vasoconstriction, leading to increased 
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capillary pressure and leakage (Hultgren 1996, Bärtsch et al. 2005). Endothelial 
dysfunction may also play a part in causing the excessive pulmonary hypertension 
of HAPE through impaired release of relaxing factors and augmented release of 
vasoconstrictors (Basnyat and Murdoch 2003). Exaggerated hypoxic pulmonary 
vasoconstriction is associated with impaired nitric-oxide synthesis (Busch et al. 
2001) and there is a hypothesis that HAPE-susceptible people may have a defect in 
nitric-oxide synthesis, possibly due to reduced nitric-oxide synthase activity (Droma 
et al. 2002). A further mechanism that may contribute to the pathophysiology of 
HAPE is a diminished capacity for alveolar fluid reabsorption and inflammation. It 
is conceivable that the pressure required for transvascular leakage decreases when 
the integrity of the alveolar capillary barrier is weakened. Thus any inflammatory 
process of the respiratory tract that extends to the alveolar space would facilitate 
oedema formation at lower capillary pressures. Any reduction in the capillary bed 
should enhance oedema formation because of reduced reserve capacity and thus 
higher resistance to increased flow (Bärtsch et al. 2005).
Gene polymorphisms that confer differences in the activities of key enzymes 
may play a part in the pathogenesis of HAPE (Basnyat and Murdoch 2003). HAPE 
is positively associated with two eNOS gene polymorphisms (G894T-variant and 
27-base pair variable numbers of tandem repeats) and HLA-DR6 and HLA-DQ4 
alleles, which are associated with vascular diseases such as essential hypertension 
and coronary heart disease. However, an investigation in Caucasians equivalent to 
the Japanese study did not find an association between susceptibility to HAPE and 
a number of eNOS polymorphisms, including the G894T variant or HLA-DR6 and 
HLA-DQ4 alleles (Bärtsch et al. 2005, Stearn and Grissom 2008).
The proposed pathophysiology of HAPE is presented in Figure 3.
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HVR=hypoxic ventilatory response. HPVR=hypoxic pulmonary vascular response. 
Figure 3. Proposed pathophysiology of high-altitude pulmonary oedema. Adopted from Basnyat and 
Murdoch 2003, originally in Schoene et al. 2001.
2.4. SYMPTOMS AND DIAGNOSIS
AMS is diagnosed according to a recent gain in altitude, the presence of headaches, 
and at least one of the following symptoms: gastrointestinal upset, fatigue, dizziness, 
or insomnia (Hackett and Oelz 1992). Symptoms of HAPE consist of dyspnoea with 
exercise, progressing to dyspnoea at rest, and a dry cough which then becomes 
productive with blood stained sputum. Crackles may be present on auscultation of 
the chest. Increasing weakness, poor exercise tolerance, profound hypoxemia, and 
death may occur if the condition is not treated (Barry and Pollard 2003, Imray et al. 
2011). Arterial oxygen saturation (SpO
2
) has said to be diagnostic for HAPE if it is 
less than 70% below 5500 m altitude (Peacock 1998) but the degree of desaturation 
alone is not a reliable sign of high altitude pulmonary oedema (Sartori et al. 2002).
HACE is usually preceded by acute mountain sickness. Headache, nausea and 
vomiting, hallucination, disorientation, and confusion are often seen; seizures are 
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less common. Clinical signs include: ataxia, a common early feature that may be 
disabling and is often the last sign to disappear during recovery; a progressive 
deterioration in consciousness, proceeding to coma and death; and papilledema 
and retinal haemorrhages. Focal neurological signs may occur, but in the absence of 
other signs and symptoms of cerebral oedema these should prompt consideration of 
other diagnoses (Barry and Pollard 2003). Severe illness due to HACE may develop 
over a few hours, especially if the prodromal signs are ignored or misinterpreted, 
and may be accompanied by high altitude pulmonary oedema.
Symptoms of acute mountain sickness are commonly misattributed to viral 
infection, alcohol hangover, exhaustion, or dehydration. Fever is often absent in 
acute mountain sickness, however. Use of alcohol or other drugs should be excluded 
when taking a history. If rest and rehydration do not improve symptoms, fatigue and 
dehydration are unlikely to be the primary cause. A patient with relevant symptoms 
who has recently ascended to a new altitude is likely to have altitude sickness, and 
he should be treated for altitude sickness until another disease process is proven 
(Imray et al. 2011).
2.4.1. Lake Louise Questionnaire
Symptoms of acute mountain sickness can be quantified by using the Lake Louise 
Scoring system (LLS) (Table 1), (Roach et al. 1993). It is easy to use and it has been 
widely adopted for use in the field (Imray et al. 2011). Because LLS was originally 
designed in 1991 for assessing the severity of symptoms of AMS as an epidemiological 
research tool, its usefulness to direct the management of an individual case is limited 
(Imray et al. 2011). The LLS questionnaire was originally made in English; it may 
not always be understood by those whose first language is not English and may 
be too complex for use with young children. Fewer symptoms of acute mountain 
sickness were reported using the standard Lake Louise questionnaire compared with 
a questionnaire using age appropriate language or visual representations (Southard 
et al. 2007). Concordantly, a simple visual analogue score has also been reported to 
be a simple effective measure of the severity of acute mountain sickness (Wagner 
et al. 2007).
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Symptom Score
1. Headache
No headache 0
Mild headache 1
Moderate headache 2
Severe, incapacitating 3
2. Gastrointestinal symptoms:
No gastrointestinal symptoms 0
Poor appetite or nausea 1
Moderate nausea or vomiting 2
Severe nausea and vomiting, incapacitating 3
3. Fatigue/weakness:
Not tired or weak 0
Mild fatigue/weakness 1
Moderate fatigue/weakness 2
Severe fatigue/weakness, incapacitating 3
4. Dizzy/light-headedness:
Not dizzy 0
Mild dizziness 1
Moderate dizziness 2
Severe, incapacitating 3
5. Difficulty with sleeping:
Slept well as usual 0
Did not sleep as well as usual 1
Woke up many times, poor night’s sleep 2
Could not sleep at all 3
Clinical assessment:
6. Change in mental status:
No change 0
Lethargy/lassitude 1
Disoriented/confused 2
Stupor/semi-consciousness 3
7. Ataxia (heel to toe walking):
No ataxia 0
Manoeuvres to maintain balance 1
Steps off line 2
Falls down 3
Cannot stand 4
8. Peripheral oedema:
No oedema 0
One location 1
Two or more locations 2
Table 1. Lake Louise acute mountain sickness questionnaire. An individual has acute mountain sickness 
as assessed by the Lake Louise self-assessment scoring system (questions 1-5) if they fulfil the 
following criteria: (1) recent ascent at high altitude, (2) headache present, and (3) the total 
symptom score above 3 (Hackett and Oelz 1992).
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An abbreviated version of the LLS, the Lake Louise AMS Self-Report Score 
and its application Clinical Assessment Score Questionnaire is easy to use even for 
non-medical persons (Hackett and Oelz 1992). AMS is diagnosed according to a 
recent gain in altitude, the presence of headaches, and at least one of the following 
symptoms: gastrointestinal upset, fatigue, dizziness, or insomnia. Symptoms 
and clinical findings, such as peripheral oedema, difficulties in walking a line or 
standing, and changes in mental state, were graded from 0 to 4, with 0 meaning 
no symptoms and 1 to 4 meaning mild, moderate, severe, and extremely severe 
symptoms, respectively. A sum for self-reported symptoms of 2-4 points or above, 
including headache, indicated AMS. The cut of points vary a little bit but usually 
three points is classified for AMS and four if Clinical Assessment Score is added. The 
Lake Louise AMS Self-Report Score has become the gold standard of assessing AMS 
by non-clinicians, including expedition leaders and commercial guides, who often 
make decisions about a climber’s ability to continue trekking (van Roo et al. 2011).
AMS may be classified as either a mild, moderate, or severe form (Luks et al. 
2010). AMS may be considered to be mild if there is a headache plus 1 or more other 
symptom (nausea/vomiting, fatigue, lassitude, dizziness, difficulty sleeping) and all 
symptoms are of mild intensity. The score for self-reported mild AMS is 2-4, and in 
moderate to severe forms of AMS it may be 5-15. The clinical diagnosis of HACE is 
based on worsening AMS symptoms with headache, change in mental status, and 
ataxia (tested with heel-to-toe walking in a line). High altitude symptoms that fail to 
meet the criteria of AMS (LLS points 1 or 2) can be defined as high altitude-related 
symptoms (Rodway et al. 2003). 
2.5. PREVENTION AND TREATMENT
2.5.1. Ascent rate
Ascending slowly and allowing time for acclimatisation is the best way of preventing 
AMS (Basnyat and Murdoch 2003, Stream and Grissom 2008, Imray et al 2011). 
The gold standard is that above 2500-3000 m ascent should be less than 300-600 m 
per day, with a rest day for every 1000 m climbed or for every 3-4 days (Hacket and 
Roach 2001, Basnyat and Murdoch 2003, Luks et al. 2010). In planning the rate of 
ascent, the altitude at which someone sleeps is considered more important than the 
altitude reached during waking hours, which means that it is permissible to ascend 
more than the recommended daily rate, as long as descent is made before sleeping 
(climb high, sleep low). Determining an ideal ascent rate, however, is difficult, and 
varies from person to person. Subjects with a prior history of AMS or HAPE should 
choose a lower ascent rate, and pharmacologic prophylaxis is recommended as 
adjunctive therapy in some cases.
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2.5.2. Hypoxic preconditioning
The use of hypoxic pre-conditioning for the prevention of AMS is becoming more 
common, although currently the supporting evidence base is limited (Imray et al. 
2011). A night spent at an intermediate altitude (1500–2500 m) before ascent to 
high altitude will aid acclimatisation (Basnyat and Murdoch 2003). One to three 
weeks daily pre-acclimatization in a hypobaric chamber several days before the 
ascent to altitudes of 4300 m has been shown to reduce incidence and severity of 
AMS (Imray et al. 2011).
2.5.3. Pharmacological agents
Pharmacological prophylaxis may be warranted in some situations. These situations 
include rapid ascent to altitudes higher than 3000 m (e.g., flying to La Paz, Bolivia, at 
3625 m), and for people with increased susceptibility to AMS. In rare circumstances 
(e.g., military or rescue teams who must ascend rapidly to and perform physical 
work at altitudes above 3500 m), pharmacological prophylaxis is recommended 
(Luks et al. 2010). This strategy should be avoided except in these particular or 
other emergency circumstances that mandate a very rapid ascent.
Acetazolamide is the preferred drug, and in emergency situations consideration 
can be given to the concurrent use of acetazolamide and dexamethasone (Luks et 
al. 2010, Imray et al. 2011). The recommended adult dose for prophylaxis is 125 
mg twice daily (Table 2). The pediatric dose (< 12 yrs) of acetazolamide is 2.5 mg/
kg per dose (maximum 125 mg per dose) every 12 hours (Luks et al. 2010). The 
recommended adult doses for dexamethasone are 2 mg every 6 hours or 4 mg every 
12 hours. Very high doses (4 mg every 6 hours) may be considered in very high risk 
situations, such as military or search and rescue personnel being airlifted to altitudes 
greater than 3500 m with immediate performance of physical activity, but should 
not be used outside these limited circumstances. The duration of use should not 
exceed 10 days (Luks et al. 2010). For individuals ascending to and staying at the 
same elevation for more than several days, prophylaxis may be stopped after 2 to 
3 days at the target altitude or once descent is initiated (Luks et al. 2010).
Nifedipine (30 mg extended release form orally once or twice daily) (Bärtsch et 
al 1991), phosphodiesterase-5 inhibitors sildenafil (40 mg 3 times daily) and tadalafil 
(10 mg twice daily), and inhalation of the beta-adrenergic agonist salmeterol (125 
μg twice daily) reduce the risk of developing HAPE in HAPE-prone individuals 
(Stream and Grissom 2008). Because phosphodiesterase-5 inhibitors may worsen 
AMS symptoms, including headache, and this has not been verified in large studies, 
cautious use may be an acceptable alternative for selected individuals who have 
already been observed to tolerate these drugs without ill effects. (Stream and Grissom 
2008, Luks et al. 2010).
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The usefulness of Ginko biloba products is unclear. While some studies have 
described its benefits, others found it to be ineffective compared with acetazolamide 
and placebo (Imray et al. 2011). Other options like chewed coca leaves, coca tea, 
and other coca-derived products have never been systematically studied (Luks et 
al 2010).
In low-risk situations, prophylactic medications are not necessary and individuals 
should rely on a gradual ascent profile. Prophylactic medications should be 
considered in addition to gradual ascent for use in moderate- to high-risk situations 
(Luks et al 2010).
Medication Indication preventive dosage treatment dosage
Acetazolamide AMS, HACE Oral 125 mg twice per day Oral 250 mg twice per day*
Dexamethasone AMS, HACE Oral 2 mg every 6 h or 4 mg 
every 12 h
Oral IV, IM AMS: 4 mg every 6 
h  HACE: 8 mg once then 4 mg 
every 6 h 
Nifedipine HAPE Oral 30 mg SR version, every 
12 hours or 20 mg of SR
version every 8 h
Oral 30 mg SR version, every 
12 hours or 20 mg of SR 
version every 8 h
Sildenafil HAPE Oral 50 mg every 8 h No recommendations, 
preventive dosage have used
Tadalafil HAPE Oral 10 mg twice per day No recommendations, 
preventive dosage have used
Salmeterol HAPE Inhaled 125 µg twice per day 
Oxygen Usually only at > 8000 m 
expeditions, 2-4 litres/min by 
mask or nasal cannulas
2-4 litres/min by mask initially, 
then 1-2 litres/min or titrate 
dose until SaO2 > 90 %
Portable hyperbaric 
chamber, Gammow 
bag®
Depends on model; 13-26 
kPa for a minimum of 2 hrs.; 
continued as long as necessary 
Descent AMS, 
HACE, 
HAPE
ascend only 300-600 m 
per day and to have an 
acclimatization day for every 
1000 m of altitude gained 
500 m at least, in mild cases 
stop, rest and acclimatize 1-2 
days
AMS = acute mountain sickness; HACE = high altitude cerebral oedema; HAPE = high altitude pulmonary oedema; SR = sustained 
release; IV = intravenous; IM = intramuscular.
 * Acetazolamide can also be used at this dose as an adjunct to dexamethasone in HACE treatment, but dexamethasone remains 
the primary treatment for that disorder.
Table 2. Recommended dosages for medications used in the prevention and treatment of altitude illness 
(Imray 2011, Barry and Pollard 2003, Luks et al. 2010).
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2.5.4. Treatment 
The principles of treatment for AMS are to avoid further ascent until symptoms 
have resolved, to descend if there is no improvement or if symptoms worsen, and 
to descend immediately at the first signs of cerebral or pulmonary oedema.
When practical, an accompanied descent of 300-1000 m remains the most 
effective treatment for all high altitude illnesses. Other treatments for acute mountain 
sickness reflect the varying severity of the clinical symptoms. Rest alone is frequently 
sufficient for mild AMS (LLS 2-4) with maintenance of hydration and combined 
with symptomatic relief of headache with paracetamol or ibuprofen (Imray et al. 
2011). Additional pharmacotherapy may be used in conjunction with the treatments 
above, especially if descent is impossible and oxygen is unavailable. The useful 
medications and dosages are presented in Table 2.
For moderate to severe acute mountain sickness (LLS 5 or more) acetazolamide, 
dexamethasone, or both are the best acute therapy, provided that the patient has 
not taken these drugs prophylactically (Luks et al. 2010). Analgesics and antiemetics 
may afford symptomatic relief. Descent and oxygen are the treatments of choice for 
moderate to severe AMS. Even a small descent of 400–500 m may be sufficient to 
relieve symptoms (Stream and Grissom 2008). Individuals should descend until 
symptoms resolve, unless impossible due to terrain. Symptoms typically resolve 
following a descent of 300 to 1000 m, but the required descent will vary between 
persons. Individuals should not descend alone, particularly in cases of HACE (Luks 
et al. 2010). Oxygen delivered by nasal cannula at flow rates sufficient to raise 
arterial oxygen saturation (SpO
2
) to greater than 90% provides a suitable alternative 
to descent (Stream and Grissom 2008, Luks et al. 2010). Use is not required in 
all circumstances and is generally reserved for severe cases when descent is not 
feasible. The supply of oxygen may be limited at remote high altitude clinics or on 
expeditions, necessitating careful use of this therapy.
The most reliable treatment for HAPE is immediate descent (at least 500 to 1000 
m), supplemental oxygen, or both (Stream and Grissom 2008). Oxygen should be 
provided at a high enough fraction of inspired oxygen to achieve an arterial oxygen 
saturation of greater than 90% (Stream and Grissom 2008, Luks et al. 2010). If 
oxygen is not available and descent is unsafe or impossible, a portable hyperbaric 
chamber can simulate a descent of 1500-2000 m and is a good temporizing measure 
before definitive therapy is possible with descent to a lower altitude (Luks et al. 
2010). Optimal therapy includes ensuring passive descent and keeping the patient 
warm, which will minimize any additional exercise- or cold-induced sympathetic 
contribution to the condition (Stream and Grissom 2008). Continuous positive 
airway pressure may also be useful for the treatment of HAPE; a portable device 
has been developed that can be used in the mountains. Slow release nifedipine may 
be useful as an adjunct to descent and oxygen (Stream and Grissom 2008, Luks 
et al. 2010) (Table 2).
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3. PREDICTION OF AMS
Many researchers have looked for ways to predict AMS. Low hypoxic ventilatory 
response (HVR) has been proposed as a marker of susceptibility to AMS (King and 
Robinson 1972, Moore et al. 1986), but some field studies have found no connection 
between HVR and AMS (Sutton et al. 1976, Hohenhaus et al. 1995, Bärtsch et 
al. 2002). Very high HVR has been reported in successful climbers at extreme 
altitudes (West 2000), but the high HVR is not necessary for successful climbing 
after acclimatization to extreme altitudes (Bernardi et al. 2006). In addition, low 
end-expiratory PO
2
 in normoxia (Savourey et al. 1995), a short breath-holding time 
and increased gag reflex (Austin and Sleigh 1995), ventilation changes during brief 
normobaric hypoxia (Schirlo et al. 2002), or changes in SpO
2
 during short term 
exposure for normobaric or hypobaric hypoxia (Burtscher et al. 2008) would enable 
the detection of those climbers who are susceptible to AMS. 
Monitoring heart rate (HR) and arterial oxygen saturation at rest (R-SpO
2
) have 
been proposed as simple indicators of inadequate acclimatisation to high altitudes 
and impending AMS (Roach et al. 1998, Burtscher et al. 2008). SpO
2 
value after 
light exercise has been shown to be a convenient means of estimating the level of 
high-altitude acclimatization among healthy subjects (Saito et al. 1995). Previously, 
normo- and hypobaric exercise tests have been shown to indicate susceptibility to 
AMS. Savourey et al. proposed arterial oxygen content (CaO
2
), based on haemoglobin 
concentration and SaO
2
 by pulse oximetry during submaximal exercise after 30 min 
in hypoxia as a good predictor of impending AMS (Savourey et al. 2007). Similarly, 
oxygen saturation during exercise in the early hours of exposure at 4300 m has been 
found to correlate with the subsequent development of impending AMS (Staab et 
al. 2006). Arterial oxygen saturation measurement during, or immediately after, 
exercise has been shown to be useful in anticipating AMS (Roach et al. 1998), but it is 
susceptible to many disruptive factors (for example temperature) (Luks and Swenson 
2011). Changes in heart rate variation (HRV) parameters during acclimatization 
and AMS at 3180-4559 m altitudes have been shown in several studies (Loeppky et 
al. 2003, Lanfranchi et al. 2005, Chen et al. 2008, Huang et al. 2010). Modesti et 
al. generated a predictive index combining clinical and haematological parameters 
(oxygen saturation, haematocrit, day of expedition, and maximum velocity of clot 
formation) measured at an intermediate step on the way to the top to predict AMS 
within 48 h of reaching high altitude (Modesti et al. 2011). In the work described 
here, however, SpO
2
 and HRV measurements are utilized as a predictor of AMS, 
given their practical usefulness in the field (vide infra).
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3.1. OXYGEN SATURATION (SPO2)
The O
2
 delivery system in the body consists of the lungs and the cardiovascular 
system. O
2
 delivery to a particular tissue depends on the amount of O
2
 entering 
the lungs, the adequacy of pulmonary gas exchange, correct ratio of ventilation/
perfusion, the blood flow to the tissue, and the capacity of the blood to carry O
2
. The 
amount of O
2
 in the blood is determined by the amount of dissolved O
2
, the amount 
of haemoglobin in the blood, and the affinity of the haemoglobin for O
2
 (Ganong 
1983). Oxygen saturation (SpO
2
) is a relative measure of the amount of oxygen that 
is dissolved or carried in a blood. Oxygen saturation can be measured regionally and 
non-invasively. Arterial oxygenation is commonly measured using pulse oximetry. 
A pulse oximetry monitor displays the percentage of arterial haemoglobin in the 
oxyhemoglobin configuration. Acceptable normal ranges for healthy subjects are 
from 95 to 99%. A pulse oximetry sensor is placed on a thin part of the patient’s 
body, usually a fingertip. Light of two different wavelengths is passed through the 
tissue to a photo detector. The changing absorbance at each of the wavelengths is 
measured, allowing determination of the absorbances due to the pulsing arterial 
blood alone, excluding venous blood, skin, bone, muscle and fat (Severinghaus et 
al. 1987). In addition, peripheral tissue saturation can be measured using near-
infrared spectroscopy, which makes it possible to measure both oxygenated and 
deoxygenated haemoglobin in both brain and muscle in various environmental 
conditions (Peltonen et al. 2007, Peltonen et al. 2009).
3.1.1. SpO2 normally at rest and exercise
When blood is equilibrated with 100% O
2
 (PO
2
 = 760 mm Hg), the haemoglobin 
becomes 100% saturated. In vivo at sea level, the haemoglobin in systemic arterial 
blood is only 97% saturated due to a slight admixture with venous blood that 
bypasses the lungs (“physiologic shunt”) (Ganong 1983).
At sea level, both an excessive alveolar-to-arterial PO
2
 difference (A-a DO
2
) ( 
> 25-30 Torr) and inadequate compensatory hyperventilation (arterial PCO
2
 > 35 
Torr) commonly contribute to exercise-induced arterial hypoxemia, as do acid- 
and temperature-induced shifts in O
2
 dissociation at any given arterial PO
2
. In 
turn, expiratory flow limitation may present a significant mechanical constraint 
to exercise hyperpnoea, whereas ventilation-perfusion ratio maldistribution and 
diffusion limitation contribute about equally to the excessive A-a DO
2 
(Dempsey 
and Wagner 1999).
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3.1.2. SpO2 at altitude
The human body performs best at sea level, where the atmospheric pressure is 
101,325 Pa or 1013.25 millibars (or 1 atm, by definition). The concentration of O
2
 in 
sea-level air is 20.9%, so the partial pressure of O
2
 (PO
2
) is 21.136 kPa. Atmospheric 
pressure decreases exponentially with altitude while the O
2
 fraction remains constant 
to about 100 km, so PO
2
 decreases exponentially with altitude as well. It is about 
half of its sea-level value at 5000 m, the altitude of the Everest Base Camp, and 
only a third at 8848 m, the summit of Mount Everest (Barry and Pollard 2003). At 
high altitude, the air is very dry but the alveolar pressure of H
2
O (PH
2
O) remains 
47 mmHg in every altitude because the respiratory system depends only on the 
temperature to maintain alveolar air humidity at 100%. The PH
2
O takes a relatively 
bigger part from total alveolar air pressure at high altitude than at sea level. This 
leads to the relatively more significant decrease to an intra-alveolar PO2 than what 
would be caused by the relative decrease of the air pressure.
The most important contributor to the maintenance of arterial oxygen content 
(CaO
2
) during acclimatization is involuntary increase in ventilation. A drop in the 
PO
2
 of the arterial blood leads to hypoxic stimulation of peripheral chemoreceptors, 
located primarily in the carotid and aortic bodies, causing an increase in the depth 
and rate of breathing. This phenomenon is known as the hypoxic ventilator response. 
Increased ventilation lowers the alveolar PCO
2
 and increases the alveolar PO
2
 (Palmer 
2010). At extreme altitudes, like at the summit of Mount Everest, alveolar ventilation 
is increased approximately 5-fold, such that the PCO
2
 is reduced to 7 to 8 mm Hg 
(West 2000). This extreme degree of ventilation limits the fall in PO
2
 to around 35 
mm Hg, even though the inspired PO
2
 is only 29% that of sea level (Palmer 2010). 
SpO
2 
decreases when altitude increases and marked hypoxemia occurs, maximum 
aerobic power is depressed and this impairs the ability to work maximally. SpO
2
 
varies over a range in normal individuals at a given altitude. It is usually lower on 
first arrival at a given altitude and rises somewhat with acclimatization (Mason et al. 
2000; Botella de Maglia and Compte Torrero 2005; Compte-Torrero et al. 2005).
3.1.3. SpO2 as a predictor of AMS
R-SpO
2
 varies in normal individuals at a given altitude (Mason et al. 2000, Compte-
Torrero et al. 2005, Botella de Maglia and Compte Torrero 2005). It has been 
shown that resting arterial hypoxemia is related to later development of clinical 
AMS (Hackett et al. 1982) and oxygen saturation at rest correlates inversely with the 
Lake Louise AMS score at 4200 m and 2659 m (Roach et al. 1998, Kao et al. 2002). 
Rathat and colleagues (1992) suggested that measuring changes in SpO
2
 at rest and 
after 5-min exercise (50 % of normoxic V O
2
max) in normoxia and hypoxia (0.115 
FiO
2
) could distinguish individuals who are susceptible to AMS. The predictive value 
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of SpO
2
 measurements and an association between decreased oxygen saturation 
and AMS have been shown at an altitude of 4200m (Roach et al. 1998) and 2659 
m (Kao et al. 2002). However, some other studies did not demonstrate such an 
association (O’Connor et al. 2004, Wagner et al. 2012, Chen et al. 2012). SpO
2 
value after light exercise (Ex-SpO
2
) has been shown to be a convenient means of 
estimating the level of high-altitude acclimatization among healthy subjects (Saito 
et al. 1995). Savourey et al. (2007) proposed arterial oxygen content (CaO
2
), based 
on haemoglobin concentration and SpO
2
 by pulse oximetry during submaximal 
exercise after 30 min in hypoxia as a good predictor of impending AMS. Similarly, 
oxygen saturation during exercise in the early hours of exposure at 4300 m has 
been found to correlate with the subsequent development of impending AMS (Staab 
et al. 2006). Peripheral arterial desaturation is further exacerbated by exercise in 
adolescents with AMS (Major et al. 2012). Ex-SpO
2 
measurements after the 6-minute 
walk test have been shown to predict a successfull climb to reach the summit of 
Aconcagua (Lazio et al. 2010). 
3.2. HEART RATE VARIABILITY (HRV)
The autonomic nervous system (ANS) is the part of the nervous system that 
controls the body’s visceral functions, including action of the heart and vascular 
tone. Part of the function of the ANS emphasises autonomic reflexes, whilst part 
of it is under central regulation. It is in close connection with the humoral system 
modulating hormonal responses and it is an essential part of the generalised stress 
reaction, inducing and modifying it. The ANS can be divided in sympathetic and 
parasympathetic branches.
Sympathetic stimulation activates the “fight or flight” reaction by increasing 
heart rate, blood pressure, and blood flow to brain, heart, lungs, and skeletal muscle. 
It also dilates pupils and the bronchial tree, and increases renin secretion in the 
kidneys (Ruffolo 1991). The parasympathetic nervous system acts in the opposite 
way to the sympathetic system. Activation of the parasympathetic nervous system 
results in decreased heart rate and inotropy, increased salivation, increased motility 
of the gastrointestinal tract, constriction of the bronchial tree, contraction of the 
pupils, and relaxation of the bladder (Ruffolo 1991). Hypoxia elicits neurohumoral 
and hemodynamic responses in the brain and lungs, resulting in overperfusion 
of microvascular beds, elevated hydrostatic capillary pressure, capillary leakage, 
and consequent edema (Hackett and Roach 2001). On the other hand, hypoxia, 
exercise, and cold environment have been shown to increase the vasoconstriction 
in pulmonary circulation (Gallagher and Hackett 2004). Individuals with acute 
altitude sickness hypoventilate (Moore et al. 1986), their sympathetic activation 
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is elevated (Mazzeo et al. 1995), and ventilatory drive in response to hypoxia is 
reduced (Barry and Pollard 2003).
3.2.1. Physiological background of HRV
Heart rate is a product of balance between intrinsic cardiac pacemaker activity and 
external control mechanisms (Singer et al. 1988). These control mechanisms include 
the ANS with predominant vagal activity during normal conditions (Kleiger et al. 
1991), humoral (renin-angiotensin -system, catecholamines) and thermoregulatory 
factors (Van Raveswaaij-Arts et al. 1993). In normal conditions, the influence of the 
control mechanisms increases fluctuation around the intrinsic regular heart rate 
(Kleiger et al. 1991, Van Raveswaaij-Arts et al. 1993).
Normal variability in heart rate, therefore, is due to the synergistic action of the 
two branches of the ANS, which act in balance through neural, mechanical, humoral, 
and other physiological mechanisms to maintain cardiovascular parameters in 
their optimal ranges and to permit appropriate reactions to changing external or 
internal conditions. The estimated heart rate of a healthy person at any point in 
time represents the net effect of the parasympathetic nerves, which slow heart rate, 
and the sympathetic nerves, which accelerate it. Emotions, thoughts and physical 
activity have an influence on these changes. Changing heart rhythms also affect the 
brain’s ability to process information, including decision-making, problem-solving, 
and creativity. The changes also affect the way a person feels (Van Raveswaaij-Arts 
et al. 1993).
3.2.2. Analysis of HRV
Heart rate variation has been analysed in clinical medicine and in research since 
the beginning of the 1970s (Antila 1979). The earliest methods were time domain 
analyses (Van Raveswaaij-Arts et al. 1993, Task Force 1996), followed by power 
spectral analysis, and non-linear dynamic methods that have been widely used in 
clinical medicine.
Time domain analysis
Time domain measures are perhaps the simplest way to analyse variations in heart 
rate. The measured variables are the mean interval between normal QRS-complexes 
(mean RR (NN)-interval), mean HR, the difference between longest and shortest 
NN-interval, and the difference between day and night heart rate. More complex 
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measures can be calculated using statistical time domain methods and geometrical 
methods. The recommended recording period is 24 h but should be for at least 5 
min. (Van Raveswaaij-Arts et al. 1993, Task Force 1996).
 Statistical methods can be divided into two classes; those derived from direct 
measurements of the NN-intervals or instantaneous HR, and those derived from 
the differences between NN-intervals. The standard deviation of the NN intervals 
(SDNN) is used in 24-hour recordings (Van Raveswaaij-Arts et al. 1993, Task Force 
1996). SDNN reflects all the cyclic components that are responsible for variability 
during the recording period or the smaller segment used for calculation. The shorter 
the recording period, the shorter is also the cycle length that SDNN estimates. The 
variance of HRV also increases with the length of the recording period. SDNN is not a 
good statistical quantity due to its dependence on the length of the recording period. 
The standard deviation of the mean NN-interval is used for successive 5-minute 
recordings. It estimates the changes in heart rate due to cycles longer than 5 min. 
SDNN index is the mean of the 5-min SDNN and measures the changes due to 
cycles shorter than 5 min (Van Raveswaaij-Arts et al. 1993, Task Force 1996). The 
square root of the mean squared differences of successive NN-intervals (RMSSD) 
correlates well with the HF power of power spectral analysis. The most important 
limit of the statistical methods used is that they detect only high-frequency variations 
originating from changes in ANS activity (Van Raveswaaij-Arts et al. 1993, Task 
Force 1996).
Series of NN intervals can be converted into a geometric pattern and a simple 
formula is used to estimate the variability based on the properties of the resulting 
pattern. Generally, there are three possibilities that can be used in geometrical 
methods. First, a basic measurement of the geometric pattern is converted into the 
measure of HRV. Second, the geometric pattern is interpolated by a mathematically 
defined shape and the parameters of this shape are used as measures of HRV. 
Third, the geometric shape is classified into several pattern-based categories which 
represent different classes of HRV (Van Raveswaaij-Arts et al. 1993, Task Force 
1996).
HRVtriind is the HRV triangular index and it is the integral of the density 
distribution (the number of all NN intervals) divided by the maximum of the density 
distribution (number of NN intervals in the modal bin). The numbers explained in 
the brackets can be used as an approximation when the measurement of NN intervals 
is on a discrete scale. The number of NN intervals is dependent on the length of 
the bin, that is, the precision of the discrete scale of measurement. The triangular 
interpolation of NN interval histogram is the baseline width of the distribution 
measured as a base of a triangle, which is fitted to the histogram and approximates 
the NN interval density distribution. The triangle is found based on the minimum 
square difference to the original NN interval density distribution. (Van Raveswaaij-
Arts et al. 1993, Task Force 1996). Geometrical methods are quite insensitive to 
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the analytical quality of the series of NN intervals, but there must be rather many 
NN intervals to construct a geometric pattern, thus a recording should be at least 
20 min. (Van Raveswaaij-Arts et al. 1993, Task Force 1996).
Frequency domain analysis
In power spectral analysis, the lengths of successive normal RR intervals (RRI, 
in milliseconds) are plotted against time as a tachogram. Variation of respiratory 
frequency and arrhythmias change the stationary of RR intervals and influence 
the analysis. Thus, standardisation of respiratory frequency is obligatory to receive 
stationary conditions (Task Force 1996).
The mathematical transformation (Fast Fourier Transform) of HRV data 
into power spectral density is used to discriminate and quantify sympathetic 
and parasympathetic activity and total autonomic nervous system activity (Van 
Raveswaaij-Arts et al. 1993, Task Force 1996). Power spectral analysis provides the 
basic information of power distribution as a function of frequency. The methods to 
calculate power spectral density can be divided into non-parametric and parametric. 
The non-parametric methods use quite an easy algorithm and the processing is fast. 
The parametric methods, like methods based on autoregressive models, provide 
smoother spectral components which can be distinguished independently of pre-
selected frequency bands, easy post-processing of the spectrum with an automatic 
calculation of high and low frequency power components, and easy identification 
of the central frequency of each component. Furthermore, the estimation of power 
spectral density is accurate even on a small number of samples. (Van Raveswaaij-
Arts et al. 1993, Task Force 1996).
Three main spectral components are distinguished in a spectrum calculated 
from short-term recordings of 2 to 5 min: very low frequency (VLF, 0-0.04 Hz), low 
frequency (LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-0.4 Hz) components. 
Measurement of VLF, LF, and HF components is usually made in absolute values of 
power, but LF and HF can also be measured in normalized units (n.u.). Normalized 
units are calculated by dividing the absolute power of a certain bandwidth with the 
total spectral power minus VLF component. The LF/HF-ratio is also commonly used 
to describe the balance of ANS. When analysing long-term recordings, the power 
spectral density also includes an ultra-low frequency component (ULF, 0-0,003 
Hz) (Task Force 1996).
According to the Task Force of the European Society of Cardiology, the preferred 
duration of ECG recordings for computing short-term HRV components is 5 
minutes. The recording should last at least 10 times the wavelength of the lowest 
frequency bound of the investigated component. Thus a recording of approximately 
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1 minute is needed to assess the HF and approximately 2 minutes are needed to 
address the LF component (Task Force 1996).
Poincaré plot analysis
Poincaré plot (or Lorenz plot) analysis is a nonlinear method for HRV analysis and 
it gives a visual and quantitative analysis of RR-intervals. Quantitative analysis of 
the Poincaré plot is usually performed by calculating the standard deviation along 
two diagonal axes, one of them being the line of identity at 45º to the normal axis 
and it separately measures instantaneous short-term (beat-to-beat) variability (SD1), 
long-term continuous variability of all RR -intervals (SD2), and the SD1/SD2 ratio 
(Raetz et al 1991). A strong positive correlation exists between SD1 and the HF 
power of power spectral analysis at rest, suggesting that SD1 reflects vagal efferent 
activity. This correlation is weaker during increased sympathetic activity, however. 
On the other hand, SD2 correlates with LF and LF/HF ratio during exercise (Tulppo 
et al. 1996). SD1/SD2.ratio reflects sympathovagal balance.
3.2.3. HRV as a predictor of AMS
The exact mechanism causing AMS is unknown, but marked increase in peripheral 
sympathetic activity is a common feature of AMS and may be involved in the 
pathogenesis of HAPE (Duplain et al. 1999, West 2004). Heart rate variability 
reflects sympathetic and parasympathetic, i.e. autonomic nervous system regulation 
of HR. Several studies have shown a transient reduction in parasympathetic and 
increased sympathetic activity during acute exposure to hypobaric hypoxia (Sevre 
et al. 2001, Saito et al. 2005, Hainsworth et al. 2007), which tended to be reversed 
with acclimatization (Cornolo et al. 2004).
Under hypobaric conditions, a decrease in mean spectral power of R-R intervals 
was noted within both LF and HF frequency ranges, compared with the study 
performed in normobaria (Zuzewicz et al. 1999). A reduced R-R variability and 
relative increase in LF component at high altitude have been noted in several studies 
(Kanai et al. 2001, Bernardi et al. 1998, Hughson et al. 1994). Deterioration of cardiac 
autonomic function measured by HRV has been estimated to be more sensitive in 
the prediction or detection of AMS than clinical symptoms alone at high altitudes 
(Saito et al. 2005). Loeppky et al. showed in 2003 that AMS is accompanied by 
increased LF/HF at simulated altitude. In addition, the LF power in normalized 
units was lower in their study in subjects with AMS at an altitude of 4559 m. Huang 
et al. estimated in 2010 that low HF power in normalized units or high LF/HF at 
1300 m altitude could predict AMS at 3440 m altitude and LF power in normalized 
40
KARINEN – Acute Mountain Sickness - Prediction and Treatment During Climbing Expeditions
units has been shown to be lower in subjects with AMS (Lanfranchi et al. 2005, 
Huang et al 2010). Chen et al. demonstrated in 2008 that SDNN, LF, HF, and HF 
power in normalized units decreased significantly, but LF power in normalized 
units and LF/HF increased significantly in subjects irrespective of AMS at 3180 m 
altitude (Chen et al. 2008). In contrast, Koehle et al. and Wille et al. did not find 
HRV measurements useful for the diagnosis of AMS at 4380 m or 5500 m (Koehle 
et al. 2010, Wille et al. 2012).
4. CONCLUSION OF THE LITERATURE REVIEW
Acute mountain sickness (AMS) is a common problem while ascending at high 
altitude. AMS may progress rapidly with fatal results if the acclimatization process 
fails or symptoms are neglected and the ascent continues. It affects 25% of those 
ascending to altitudes of 1850 to 2750 m (Honigman et al. 1993), 42% at altitudes 
of 3000 m (Hackett and Roach 2001), and even 84% of those attempting Lhasa, 
Tibet (3860 m) by flying (Barry and Pollard 2003). The most common reason for 
altitude illness is too rapid ascent. There is a need for a non-invasive, specific, and 
convenient method in field conditions for the detection of inadequate acclimatization 
and impending AMS. Arterial oxygen saturation (SpO
2
) measurement is useful 
in anticipating AMS (Roach et al. 1998), but it is susceptible to many disruptive 
factors in the field (for example temperature) (Luks and Swenson 2011). Autonomic 
cardiac response to increasing altitude could be a low-cost non-invasive test to predict 
impending AMS, in addition to helping distinguish those who are at risk for AMS 
and those who are acclimatizing well. Measuring acute hypoxic ventilatory response 
before altitude exposure helps to estimate the adaptive processes of the climber but 
does not offer a practical tool for expeditions to predict AMS and control the ascent 
rate. Even SpO
2 
and HRV measurements did not offer an easy solution for predicting 
AMS (Chen et al. 2012, Wille et al. 2012), but  they may offer a practical tool for 
future expedition medics or leaders. Until such approaches are proven, prevention 
is the safest and the most efficient method in the care of AMS. Possibilities for 
medical treatment and oxygen substitution might be limited. Realising the risk of 
mountain sickness, active inquiry about symptoms and correctly timed reaction to 
them, in other words interrupting the ascent or descending, helps to reduce and 
even to prevent the development of serious problems.
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AIMS OF THE STUDY
The main aims of this thesis were to evaluate the prevalence of AMS in one of the 
most popular 6000 m peaks (study I), and evaluate some predicative measurements 
for AMS like SpO
2
 and HRV in hypobaric and hypoxic environments (study II-III). 
Two AMS cases and their treatment in the field were also presented (study IV).
The specific aims of this work were: 
1. To assess the prevalence of the signs and symptoms of acute mountain 
sickness among Finnish travellers climbing Mount Kilimanjaro, Tanzania 
(I),
2. To investigate if post-exercise oxygen saturation (Ex-SpO
2
) at high altitudes 
predicts AMS better than R-SpO
2
 or resting HR alone (II),
3. To evaluate if HRV level or HRV changes have a relationship to AMS during 
ascent and provide new information on the deterioration of cardiac autonomic 
function as measured by HRV not only at altitudes between 2400 and 5000 
m, which are most frequent among climbers, but also at extreme altitudes 
above 5000 m in field conditions (III),
4. To generate tools for AMS for non-medical persons to estimate the risk in 
field conditions (II-III), and
5. To describe a typical AMS case and the difficulties to treat AMS in the field 
(IV).
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MATERIAL AND METHODS
An observational study to investigate the incidence of AMS experienced by Finnish 
travellers during their Kilimanjaro treks was carried out at Kilimanjaro, Tanzania 
(I). The experimental studies in field conditions were carried out during seven 
expeditions to Denali (Denali 1, Denali 2, Alaska), Shisha Pangma (Tibet), Ulugh 
Muztagh (Tibet), Island Peak, and Mount Everest (Nepal and Tibet) (II-III). The 
ascent profiles during measurements for different expeditions are presented in 
Figure 4. The subjects for case study (IV) were from Shisha Pangma and Ulugh 
Mustagh expeditions.
1. THE MOUNTAINS
The peak of Kilimanjaro is 5895 m above sea level and 03.04° south in latitude 
(Coordinates are 3°4′33″S, 37°21′12″E). There are several routes to the summit and 
the easiest and the most popular is the so-called Marungu Route, where the study 
was conducted. Most Finnish tour operators represented in the area arrange treks 
via this route. The distance between the entrance and the summit is 36 km and 
there are several camps and huts along the route. Most trekkers end their climb 
at Gillman’s Point, which is on the crater rim at 5681m. Some of them continue 
around the rim to Uhuru Peak (5895 m), the highest point in Africa. These treks 
normally take six days from the Marungu gate (altitude 1800 m) to the summit 
and back. Regular camps are Mandara hut (2743 m), Horombo hut (3760 m), and 
Kibo hut (4730 m). Usually there is a rest and acclimatisation day at Horombo hut.
Denali (Mount McKinley) (Coordinates are 63°04′10″N, 151°00′27″W) is 
situated in Alaska, United States and it is the highest mountain peak in North 
America, with a summit elevation of 6194 m above sea level. The mountain is 
regularly climbed today; in 2003, around 58% of climbers reached the top. But by 
2003, the mountain had claimed the lives of nearly 100 mountaineers over time 
(Coombs and Washburn 1997). The vast majority of climbers use the West Buttress 
Route and climbers typically take two to four weeks to ascend the mountain. The 
mountain is characterized by extremely cold weather. According to the National 
Park Service, the lowest temperature that had been recorded was approximately 
−73 °C. In June 2002, a weather station was placed at the 5800 m level. The 
weather station recorded temperatures as low as −59.7 °C on December 1, 2003. 
On the previous day, November 30, 2003, a temperature of −59.1 °C combined 
with a wind speed of 8.2 m/s to produce a North American record wind-chill of 
−83.4 °C. Temperatures as low as −30.5°C and wind-chill as low as −50.7°C have 
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been recorded by this weather station, even in July (http://en.wikipedia.org/wiki/
Mount_McKinley 4.11.2011). The measurements of this study were made at West 
Buttress Route during two expeditions at May 2001.
Shisha Pangma (Xixabangma) is the fourteenth-highest mountain in the world 
(8013 m) and is located in south-central Tibet, a few kilometres from the border 
with Nepal (Coordinates are 28°21′8″N, 85°46′47″E). Shisha Pangma is one of 
the easier eight-thousanders to climb. The standard route ascends from the north 
side, and boasts relatively easy access, with vehicle travel possible to base camp at 
5000 m (Carter 1985). The measurements of this study were made during a Finnish 
expedition in May 2002.
Ulugh Muztagh, also known as Ulugh Muztag and Muztag Feng, is an extremely 
remote mountain group on the Northern Tibet plateau. Located on the border 
between the Tibetan Autonomous Region and Xinjiang Uyghur Autonomous 
Region, it is part of the main range of the Kunlun Mountains of Central Asia. 
(Coordinates are 36°24′45″N, 87°23′06″E).
For a long time its elevation was thought to be as high as 7723 metres, but it 
was measured by a 1985 Sino-American first ascent expedition, who established 
its true elevation of 6973 m, which has since been confirmed by SRTM data and 
modern high resolution Chinese topographic mapping. The subsidiary West Peak 
was climbed by a Finnish expedition in 2003 and a height of 6925 m was confirmed 
for Ulugh Muztagh II.
There have been only a few attempts to climb Ulugh Muztagh II and several of 
them have not even been able to reach the foot of the mountain. Getting near the 
mountain requires a difficult drive across largely unpassable terrain at the elevation 
of 4300-5000 metres. Expeditions who finally climbed the mountain spent 3 weeks 
on the approach alone using 4 or 6 wheel drive vehicles (http://en.wikipedia.org/
wiki/Ulugh_Muztagh 4.11.2011). The measurements were made during this Finnish 
first ascent expedition in September 2003.
Island Peak (Imja Tse) is a 6189 m high mountain in the Himalayas of eastern 
Nepal, ten kilometres south from Mount Everest. The peak was named Island Peak 
in 1951 by Eric Shipton’s party since it appears as an island in a sea of ice when 
viewed from Dingboche. The peak was later renamed in 1983 to Imja Tse, but 
Island Peak remains the popular choice. (http://www.nepalmountaineering. org/
Imja Tse. 4.11.2011). Island Peak is one of the most popular trekking peaks given 
its difficulty (alpine PD+) and accessibility especially when supported by a Nepalese 
climbing guide. Coordinates are 27°55′21″N, 86°56′10″E. To climb Island Peak, 
the route follows the Everest base camp route up to the Pheriche at 4300 m and 
separates towards Dingboche. The base camp is situated at 5087 metres and High 
Camp is at around 5600 metres. The measurements were made during a Finnish 
expedition in November 2006.
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Mount Everest (Chomolungma, Sagarmāthā) is the world’s highest mountain, 
with a peak at 8848 m above sea level. It is located in the Mahalangur section of 
the Himalayas on the Nepal-China (Tibet) border. Coordinates are 27°59′17″N, 
86°55′31″E. Mt. Everest has two main climbing routes, the southeast ridge from 
Nepal and the northeast ridge from Tibet, as well as many other less frequently 
climbed routes. The measurements were made during Finnish Everest expeditions 
in 2005 (the northeast ridge route) and 2009 (the southeast ridge route).
The ascent of the 2005 expedition to the base and advanced base camps were 
done first by car from Nepal via Kodar-Nyalam-Rongbuk Glacier, then setting up 
Base Camp at 5200 m on a gravel plain just below the glacier. To reach Camp II, 
climbers ascend the medial moraine of the east Rongbuk Glacier up to the base of 
Changtse at around 6100 m. Camp III (ABC – Advanced Base Camp) is situated 
below the North Col at 6500 m.
The ascent of the 2009 expedition to the Everest south side basecamp (EBC) was 
done via the normal EBC trekking route. Expeditions usually fly into Lukla (2860 m) 
from Kathmandu and pass through Namche Bazaar (3500 m). Climbers then hike 
to Base Camp via Pheriche (4300 m), where the route to Island Peak separates. It 
usually takes six to eight days, allowing for proper altitude acclimatization in order 
to prevent altitude sickness. Climbing equipment and supplies were carried by yaks 
and human porters to Base Camp on the Khumbu Glacier.
In Denali, Shisha Pangma, Ulugh Muztagh, and both Everest expedition, no 
porters were used. The climbers carried all their supplies above the base camps. 
Ascent profiles are presented in figure 1.
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Figure 4. The typical ascent profiles of the mountains
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2. SUBJECTS
The study groups consisted of participants of several different expeditions. A total 
of 186 different climbers were evaluated. Among them, 70 were females and 116 
males. Study I was observational, to investigate the incidence of AMS experienced 
by Finnish travellers during their Kilimanjaro trek. A total of 130 participants from 
seven different trekking groups were asked to complete a Lake Louise self-report 
and clinical assessment score questionnaire on their way up Kilimanjaro, of which 
112 were completed (study I) (Table 3). In study II, 83 ascents made by 74 different 
climbers were evaluated during their expeditions to Denali, Shisha Pangma, Ulugh 
Muztagh, Pheriche, Island Peak, and Mount Everest (Table 4). Some subjects in 
study III were also in study II; a total of 36 climbers from the expeditions to Denali, 
Shisha Pangma, and Mount Everest were evaluated (Table 5). The subjects for the 
case study (study IV) were from Shisha Pangma and Ulugh Muztagh expeditions.
2.1. FINNISH TREKKERS ON MOUNT KILIMANJARO (I)
Most of the Finnish Kilimanjaro trekkers were middle-aged or older people wishing 
to have an African experience, including a safari in the local national park and a 
climbing trek to Kilimanjaro. Most of them have no earlier climbing or high altitude 
experience and participated in a commercial trek via a Finnish tour operator during 
the winter season of 2006-2007. Information collected included demographic data, 
signs and symptoms experienced in the past 24 hours, earlier AMS, HACE or HAPE 
and experiences of altitudes over 3000 m (previous altitude experience, AE) or 5000 
m (previous high altitude experience, HAE), use of medications (acetazolamide or 
others), the presence of chronic or other pulmonary disease, and smoking habits. In 
every group there was a Finnish guide trained in the management of high altitude 
illness and in the Lake Louise AMS scoring system (LLS). He was also trained to 
evaluate the signs and symptoms of AMS and he made the clinical assessment 
portion of the LLS. Each subject completed the questionnaire in camp every morning 
before continuing the trek and at Gillman’s Point if they reached it (Table 3).
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Female
(n=58)
Male
(n=54)
Total
(n=112)
Age, years (mean, range 16-74 yrs.) 50 52 51
BMI (mean) 23 25 24
Smokers (n) 4 8 12
Respiratory, cardiovascular and/or metabolic disease (n) 11 14 25
Acetazolamide 250 mg once a day (n) 8 2 10
No earlier altitude experience (n) 45 39 84
Earlier altitude experience (n) 11 8 19
Earlier high altitude experience (n) 2 7 9
Table 3. Demographic data (including gender, age, BMI, smoking habits, chronic diseases and use of 
acetazolamide) of the study I population
2.2. SPO2 AND AMS (II)
Study II was concentrated on the evaluation of the predicative value of oxygen 
saturation measurements for AMS during ascent at altitudes of 2400-5300 m, which 
were considered critical altitudes for acclimatization during ascent. The study was 
conducted in 2001-2009 during eight expeditions to Denali (Denali 1, Denali 2), 
Shisha Pangma, Ulugh Muztagh, Pheriche, Island Peak and Mount Everest (Table 4).
A total of 83 ascents made by 74 (64 men, 10 women) different climbers were 
evaluated. Only healthy, non-smoking climbers participated in this survey. Their 
mean ± SD age during the ascents was 35 ± 9 yrs. and maximal oxygen uptake (
V O
2max
) 54 ± 10 ml/kg/min (Table 4). None of the subjects had been exposed to 
an altitude above 1000 m within six months prior to this study. They were all 
lowland dwellers and recreational mountaineers, and during the expeditions none 
had taken acetazolamide as an AMS prophylaxis. Two climbers were taking regular 
medication for asthma but no one was using oral steroids, salmeterol, sildenafil, or 
nifedipine. All expeditions were organized in April-May. Ascent profiles were similar 
at sleeping altitudes but five expeditions had faster and three slower ascent rate. 
Before the expeditions, all members underwent a medical examination including 
resting 12-lead ECG and flow volume spirometry. To examine their exercise 
responses and to measure maximal oxygen uptake (V O
2max
), they performed an 
incremental clinical exercise test on a cycle ergometer (Ergoline 800S, Ergoline 
GmbH, Bitz, Germany). They started cycling at 20 W and work rate was increased 
stepwise 20 W/min up to volitional fatigue. A 12-lead ECG was obtained at rest 
before the exercise, and during the exercise test. All subjects had a normal ECG 
and none developed arrhythmias during the exercise test. During the exercise test, 
an alveolar gas exchange was measured breath-by-breath by a mass spectrometer 
(AMIS 2000, Innovision, Odense, Denmark) and a volume turbine (Triple V, Jaeger, 
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Mijnhardt, Bunnik, The Netherlands). Arterial saturation was recorded by pulse 
oximetry from the fingertip (Nonin 8600, Nonin Medical, Inc., Plymouth, MN, USA). 
The tests were performed mainly at the laboratory of the Foundation for Sports 
and Exercise Medicine / Department of Sports and Exercise Medicine, Institute of 
Clinical Medicine, University of Helsinki and partly at the Sports School of Finnish 
Defense Forces, Lahti.
Expedition Total
n
Female
n
Age 
(Years)
VO2max 
(ml min-1·kg-1) 
Mean 
ascent rate 
Exposure to altitude
Denali 1 17 0 28 ± 4 64 ± 6 517 m/day From 2200 m to 4300 m in 
four days, after 2 days rest, 
cont. 5300 m 
Denali 2  14 2 33 ± 7 55 ± 7 258 m/day Used nine days for the same 
route (5 days at 3500 m 
due to bad weather), 2 days 
rest at 4300 m, then cont. 
5300 m
Shisha 
Pangma 
6 0 30 ± 4 61 ± 3 500 m/day From 2300 m to 5000 m in 
four days, 2 days rest, then 
cont. 5300 m
Ulugh 
Muztagh
10 1 35 ± 10 47 ± 5 660 m/day From 1300 m to 4600 m in 
five days
Pheriche 7 0 36 ± 6 60 ± 4 600 m/day From 1300 m to 4300 m in 
five days, two days back to 
1300 m and then cont. after 
5 days from 1300 to 5300 
m in six days
Mt Everest 7 0 36 ± 6 60 ± 4 667 m/day
Island Peak 15 7 47 ± 12 40 ± 7 278 m/day From 2800 m to 5300 m in 
nine days
Mt Everest 7 0 38 ± 6 56 ± 4 278 m/day From 2800 m to 5300 m in 
nine days
Total 83 10 35 ± 10 54 ± 10
Table 4. Details of participants and ascent for each expedition (studies II-IV). Values for age and V O2max 
are mean ±SD.
2.3. HRV AND AMS (III)
In study III, the prediction of AMS was sought by heart rate variation measurements 
during ascent at altitudes of 2400-6300 m. The study group consisted of participants 
of five different expeditions to Denali (Denali 1, Denali 2), Shisha Pangma, and 
Mount Everest (Everest 1, Everest 2). The expeditions were the same as in study 
II and subjects partly the same (Table 5). Thirty six different healthy volunteers 
(2 women and 34 men) with an age range from 24 to 45 years participated in this 
study. Subjects’ mean age was 32 ± 6 years, body mass index (BMI) 25 ± 3 kg/m2 
and maximal oxygen uptake (V O
2max
) 59 ± 7 ml/kg/min.
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Characteristic no-AMS (n = 12) AMS at some altitude
(n = 24)
All (n = 36)
Age (years)(* 30 ± 5 33 ± 7 32 ± 6
BMI (kg/m2) 24 ± 1 25 ± 4 25 ± 3
V O2max (ml/kg/min) 60 ± 4 60 ± 9 59 ± 7
Values are mean ± SD. BMI = body mass index; V O2max = maximal oxygen uptake. 
Table 5. Demographic data (age, BMI and V O2max) of the study III population. There were no statistically 
significant differences in the basic characteristics between no-AMS and AMS groups.
2.4. TWO CASES OF AMS AND THEIR TREATMENT AT FIELD (IV)
Two different AMS patients and their successful treatment in the field are described, 
including the review of the current recommendations for prevention and treatment 
of AMS.
Case 1 is a 29-year-old healthy, non-smoking, and experienced Finnish 
mountaineer who participated in an expedition to a mountain over 8000 m high 
in Tibet. He had no previous history of AMS. He took four days to reach an altitude 
of 5000 m by car and spent three days there to acclimatize. After this period at 
5000 m altitude, his resting heart rate (HR) was 60 per minute and the LLS showed 
no altitude related symptoms before getting ill at 5400 m. Case 2 is a 47-year-old, 
non-smoking, and experienced mountaineer, who, however, had not earlier been 
above 4000 m altitude, participated in a car drive in the highlands of Tibet. The 
road went to the highlands from 1300 m to a village at 2930 m, where he spent two 
nights to acclimatise. During the following day, the road rose to 4800 m and finally 
reached the Tibetan plateau at 5300 m altitude where altitude illness was diagnosed.
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3. DATA COLLECTION DURING ASCENT (I-IV)
The ascent profiles during measurements at different expeditions are presented in 
Figure 5. The LLS data was collected every day at every camps and the summit of 
Mt Kilimanjaro (Study I) and SpO
2
, HRV, and LLS data were collected every day 
during ascent at altitudes of 2400 m, 3000 m, 3500 m, 4300 m, 5000 m, and 
5300 m in all expeditions (study II-IV), and up to 5600 m and 6300 m at Shisha 
Pangma (Study III-IV). 
Oxygen saturation
Adaptation of the climbers to altitude was evaluated by measuring HR and SpO
2
 at 
rest (R-SpO
2
) and immediately after moderate exercise (Ex-SpO
2
) during different 
phases of the ascent and combining these data with the Lake Louise Symptom 
Questionnaire (study II). HR was first measured in a sitting position, with HR 
monitors, after 15 min rest (Suunto T6, Vantaa, Finland; Polar S810, Kempele, 
Finland). Then R-SpO
2
 was measured by finger oximetry (Nonin Medical, Onyx 
9500, Plymouth MN, USA) while the subject was seated for an additional two 
minutes. During this period, R-SpO
2
 was observed 4 times at 15 sec intervals and 
the average R-SpO
2
 of these was recorded for data analysis. Ex-SpO
2
 at altitude was 
measured with a standard walking test. The climber walked and controlled his speed 
with the HR monitor so that HR was approximately 150 beats / minute during 3-5 
min walking. Temperature varied between + 20 to -15 °C and hands were covered 
by mittens during walking, which ended inside a tent. The inside temperature was 
mostly between + 5 and 20 °C because of extensive solar radiation or a stove. 
Immediately after the cessation of walking, SpO
2
 was measured in sitting position 
by finger oximetry four times at 5 sec intervals during the first 15 s of recovery. 
The first value was recorded immediately when the subject stopped, the next one 
after 5 sec, the third after 10 sec and the last one after 15 sec. The average of these 
values was recorded as Ex-SpO
2
 for data analysis. The main researcher took the 
measurements and AMS scoring by interviewing subjects and looking for the clinical 
signs. When the Denali 1 and Denali 2 groups were at different camps, a trained 
medical advisor took the measurements and AMS scoring. During all expeditions, 
HR, R-SpO
2,
 and Ex-SpO
2
 were measured at altitudes of 2400 m, 3000 m, 3500 m, 
4300 m, and 5300 m. Measurements were made in the morning after a night at that 
altitude. SpO
2
 was observed to decrease after 15 seconds, but its measurement was 
attempted prior to its decline. During the first 15 sec, SpO
2
 values did not change 
much, only a 0-1% unit, thus quite accurately reflecting SpO
2
 during exercise.
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Heart rate variation
In study III, HRV data (RR-intervals) collection was continued until the base camp 
of each mountain was reached. Measurements were performed every morning by 
heart rate monitor, after 7-8 hrs night rest, before doing anything else at that altitude 
(Suunto T6, Suunto, Vantaa, Finland or S810, Polar Electro, Kempele, Finland). 
HR recordings were made in the supine position, after at least 15 min of rest in the 
same position, while each subject lay quietly and breathed spontaneously. Then 
subjects started their HR monitors and continued lying down for three minutes. 
The last two minutes were chosen for data analysis. According to the Task Force of 
the European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology (Task Force 1996), the preferred duration of ECG recordings for 
computing short-term HRV components is 5 minutes. The recording should last 
at least 10 times the wavelength of the lowest frequency bound of the investigated 
component (Task Force 1996). Thus a recording of approximately one minute is 
needed to assess the HF and approximately 2 minutes are needed to address the LF 
component. Autonomic cardiac function was assessed by analysis of R-R intervals 
(RRI). The duration of stationary RRI time series was 2 minutes, which should be 
adequate for the determination of the HRV components evaluated (Koskinen et 
al. 2009).
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Figure 5. Ascent profiles during measurements at different expeditions.
After the HRV and SpO
2
 measurements, subjects were scored according to the 
Lake Louise AMS scoring (LLS) system, which include a self-report questionnaire 
related to the presence and severity of symptoms and a clinical assessment (Hackett 
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and Oelz 1992). The LLS was obtained by adding the score of the clinical section 
to the self-report questionnaire. AMS was diagnosed according to a recent gain in 
altitude, the presence of headaches, and at least one of the following symptoms: 
gastrointestinal (GI) upset, fatigue, dizziness, or insomnia. To retrospectively study 
if HRV changes could have predicted AMS at higher altitudes, the study group was 
divided into two groups: 1) if the LLS was more than or equal to 3 at any altitude, 
the subject was assigned to the AMS group, and 2) if the LLS was 0-2 at every 
altitude measured, the subject was assigned to the no-AMS group.
Analysis of HRV data
Data processing and analysis were performed after the expeditions by Polar 
Precision Performance software (version 3.02.007) and Kubios software (version 
2.0) (Niskanen et al. 2004). Areas of ectopy or artifact were identified and fixed 
by manual or automatic error correction. Segments containing ectopy or artifact 
more than 5% were excluded from the data analysis. Analysis of HRV was done for 
stationary 2-minute data segments. The power spectra were quantified by measuring 
the area in two frequency bands. The HF
2 min
 power was calculated for frequency 
band 0.15 – 0.40 Hz and LF
2 min
 power for frequency band 0.04 – 0.15 Hz.
4. STATISTICAL ANALYSIS (I-III)
Each data form was reviewed by the principal investigator for completeness. 
Differences in R- SpO
2
, Ex-S SpO
2
, and HR between AMS and non-AMS groups, 
as defined by Lake Louise AMS scores, were evaluated by t-test (I-II). Spearman’s 
correlations between AMS and HR, R-SpO
2
, and Ex-SpO
2
 at different altitudes 
were calculated (II). Sensitivity, specificity, and positive and negative predictive 
values were calculated (II-III). The frequency of different HRV parameters was 
assessed by 2 tests with Yates’ correction (III). Correlations between the LLS and 
clinical and autonomic variables were assessed by Pearson’s correlation (III). In all 
tests, a p-value less than 0.05 was considered significant. Continuous values are 
presented as means ± standard deviation (SD). All analyses were done with SPSS 
13.0 software for Windows (IBM, Chicago, IL, USA).
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5. ETHICAL CONSIDERATIONS
All subjects were informed about the objective of the study and the experimental 
protocol both orally and by written information about the study. Written informed 
consents were obtained from the subjects prior to the measurements, as stipulated 
in the Declaration of Helsinki. Participation in the study was on a voluntary basis 
and possible participation did not affect the medical care of the climber unless the 
study revealed information that was of medical importance. The Ethics Review 
Committees of the University of Tampere and University of Helsinki, Finland, had 
approved the study protocol. The subjects were healthy volunteers and they were not 
paid to participate in the study. There were no invasive measurements. Cessation 
of the study took place at the request of the subjects. 
55
RESULTS
1. THE PREVALENCE OF AMS ON MT KILIMANJARO (I)
In Study I, a total of 112 subjects (54 men, 58 women) completed the questionnaire 
at altitudes of 1700-3700 m, 107at 4700 m, and 38 at the summit. They were all 
low-land dwellers and recreational mountaineers. None had earlier diagnosis of 
AMS, HACE, or HAPE. The subjects ranged in age from 16 to 74 years, with an 
average age of 51 ± 10 SD (Table 3). Most trekkers were non-smokers, 9% had taken 
acetazolamide 250 mg daily as an acute mountain sickness prophylaxis and 22% 
were taking regular medication for respiratory, cardiovascular, and/or metabolic 
diseases. No one was using oral steroids, sildenafil, or nifedipine. The number of 
climbers at different altitudes and the presence of AMS are presented in Table 
6. Climbers spent two nights at Horombo hut and no data is available regarding 
how many climbers still had AMS before resuming the ascent. Those reaching the 
summit were 35 men and 24 women. From the first time climbers  43/84 (51%) 
summitted. Only 8/19 (42%) of those trekkers who had earlier altitude experience, 
and 8/9 (88%) of those trekkers who had earlier high altitude experience, reached 
the summit. All those who had earlier high altitude experience, and 13/19 (71%) 
of those who had some altitude experience, climbed higher than Kibo hut. Those 
that reached the summit included: 11/15 receiving medication for chronic illness, 
6/10 for asthma, and 5/10 using Diamox™.
The prevalence of AMS increased significantly with altitude (p < 0.05). The most 
common high altitude symptoms at 3700 m were sleeping difficulties, followed by 
headache and fatigue or weakness. At 4700 m, the most common symptoms were 
headache, fatigue or weakness, and sleeping difficulties. Only 6 subjects reported 
no signs and symptoms of AMS, HACE, or other high altitude related symptoms 
(HARS): 4 of them reached the summit and 2 turned back at 4700 m because of 
aching joints. Above Kibo Hut, and before reaching Gillman’s Point, 17 trekkers 
had three or more LLS points. Of these, 7 reached the summit and 9 turned back. 
An equal distribution of scores was found between men and women. A total of 39 
men and 45 women had AMS during their trek (75 %), 12 men and 8 women had 
HACE (18 %), and 12 men and 9 women had HARS (19 %). Twenty-two men and 17 
women reached the summit in spite of AMS symptoms mostly at altitudes of 3700, 
but also at 4700 m (Table 6). Patients suffering from AMS included 12/15 receiving 
medication for chronic illness, 9/10 for asthma, and 8/10 using acetazolamide.
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2. ARTERIAL O2 SATURATION AND AMS (II)
In study II, a total of 84 ascents, made by 73 climbers were examined. No AMS 
(LLS ≥ 3) cases were recorded at altitudes of 2400 m or 3000 m. Prevalence of 
AMS at an altitude of 3500 m was 10% (8/83 subjects), at 4300 m 21% (17/83 
subjects), and at 5300 m 37% (27/73 subjects). The total prevalence of AMS at 
altitudes 2400-5300 m was 47% (39/83 subjects) in the whole study group; 10 
climbers had AMS at two altitudes and 2 at three altitudes. In detail, in the Denali 
1 and 2 groups (AMS in 20/31 subjects), 3 climbers had moderate AMS (LLS 6-7), 
requiring assistance with descent and evacuation down (two subjects from 4300 
m and one subject from 5300 m). In the Shisha group, 5 out 6 climbers suffered 
mild AMS (LLS 4-5), but they continued climbing after two days’ rest. In the Ulugh 
group (AMS in 6/10 subjects), 5 had mild AMS and 1 had severe AMS with ataxia 
(LLS 8) at 5300 m. The subject with severe AMS had to be evacuated out with the 
assistance of a doctor. Trekking groups at Island Peak and Mount Everest Base 
Camp had 3 mild AMS cases at 4300 m and 7 at 5300 m (10/36 subjects).
Aerobic capacity, BMI, heart rate and arterial O
2
 saturation responses
In study II, subjects with AMS had better aerobic capacity ( V O
2max
 58 ± 7 vs. 51 
± 11 ml/kg/min respectively, p < 0.01), and they were younger (32 ± 7 vs. 38 ± 11 
yrs respectively, p < 0.01) than those in the non-AMS group. Four AMS subjects 
were obese (BMI > 30) and AMS was also associated with BMI and weight: BMI 
was 25 ± 4 and 23 ± 2 kg/m2 (p < 0.01) and weight 77 ± 12 kg and 72 ± 7 kg (p < 
0.01) in the AMS and non-AMS groups respectively.
Arterial O
2
 saturation at rest and during exertion for climbers with no AMS and 
those experiencing AMS at that altitude are presented in Figure 6. AMS scores (LLS) 
at different altitudes and Spearman’s correlation coefficients between HR, R-SpO
2
, 
Ex-SpO
2, 
and AMS at different altitudes are presented in Table 7.
58
KARINEN – Acute Mountain Sickness - Prediction and Treatment During Climbing Expeditions
Figure 6. Oxygen saturation (mean, SD) at different altitudes at rest (above) and immediately after standard 
exercise (below) in AMS and non-AMS group. (AMS+ at 3500m n = 8, 4300 m n = 17, 5300 m 
n = 27, non-AMS at 3500 m n = 75, 4300 m n = 66, 5300 m n = 46. *Different from AMS, p < 
0.01). 
Altitude Subjects/AMS cases LLS LLS in 
AMS 
cases 
Correlation coefficients: LLS vs.
HR R-SpO2 Ex-SpO2 
3500 m 83/8 0.9 (0-5) 3.9 (3-5) 0.25 # -0.03 -0.27 #
4300 m     83/17 1.6 (0-8) 4.3 (3-8) 0.30 * -0.48 * -0.62 *
5300 m     73/27 2.0 (0-8) 4.1 (3-8) 0.32 # -0.48 * -0.58 *
Table 7. Lake Louise Scores (LLS) at different altitudes (mean (range)) and Spearman’s correlation 
coefficients of heart rate (HR), arterial oxygen saturation at rest (R-SpO2) and immediately 
after exercise (Ex-SpO2) versus LLS at different altitudes. 
#p < 0.05, *p < 0.01.
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Prediction of AMS by arterial O
2
 saturation and heart rate measurements
No AMS cases were recorded at the altitude of 3000 m or below. The climbers 
experiencing AMS at 3500 m (n = 8), had higher HR at rest at 3000 m altitude 
than the non-AMS group (n=75) (82 ± 11 vs. 74 ± 10, p < 0.05). However, at 3000 
m, arterial O
2
 saturation did not differ between the groups as R-SpO
2
 was 91 ± 3 vs. 
93 ± 3% and Ex-SpO
2
 85 ± 3 vs. 86 ± 3% in AMS and non-AMS group respectively. 
As the ascent continued, the SpO
2 
measurements became more predictive.
At 3500 m, the difference between subjects subsequently suffering AMS at 4300 
m (n=17) and the non-AMS group (n=66) was obvious: both R-SpO
2 
and Ex-SpO
2
 
were lower in subjects with AMS at 4300 m than in the non-AMS group (88 ± 2 
vs. 91 ± 3, p < 0.05 and 80 ± 2 vs. 85 ± 4, p < 0.01 respectively), the difference in 
the Ex-SpO
2
 between the AMS 4300 m and the non-AMS groups at 3500 m being 
5% (95 % CI -1--4).
The subjects who subsequently developed AMS at 5300 m (n=27) had lower 
R-SpO
2 
at an altitude of 4300 m than the non-AMS group (n=46) (82 ± 4 vs. 86 ± 
5 respectively, p < 0.01). Ex-SpO
2
 was also lower in the AMS group than in the non-
AMS group (76 ± 4 vs. 79 ± 5 respectively, p < 0.01), the between-group difference 
in Ex-SpO
2
 being 3% (95% CI -1--4) at 4300 m. Elevated resting HR at 3500 and 
4300 m did not predict impending AMS at 4300 m and 5300 m (79 ± 10 vs. 73 ± 
13, ns. and 77 ± 12 vs. 76 ± 12 respectively, ns.).
The potential of screening for AMS by measuring R-SpO
2
 and Ex-SpO
2 
is 
demonstrated by two examples in Table 8. In both examples, a different limit for 
SpO
2  
is used causing changes in the predictive power of SpO
2 
for subsequent AMS. 
First, the cut-off value for SpO
2 
as a mean saturation at that altitude was chosen and 
subjects with AMS were compared to subjects without AMS at this altitude. The 
second cut-off value was chosen so that all climbers who subsequently developed 
AMS were identified. Specificity of Ex-SpO
2
 was better than that of R- SpO
2 
at 
4300 m (Table 8).
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SpO2 (%) AMS 
Score ≥ 3
AMS 
Score 
< 3
n Sensitivity
%
Specificity
%
Positive 
predictive 
value %
Negative 
predictive 
value %
R-SpO2 at 4300 m (mean 85%)
≤ 85 15 27 42 88 59 36 95
> 85 2 39 41
n 17 66 83
≤ 89 17 49 66 100 26 26 100
> 89 0 17 17
n 17 66 83
Ex-SpO2 at 4300 m (mean 78%)
≤ 78 15 14 29 88 73 52 95
> 78 2 38 40
n 17 52 69
≤ 79 17 24 41 100 52 41 100 
> 79 0 28 28
n 17 52 69
Table 8. Two examples of the sensitivity, specificity and positive and negative predictive values of different 
measurements and different R-SpO2 and Ex- SpO2 levels at 4300 m. The first cut-off value is 
mean saturation of all climbers at that altitude and we have compared subjects with AMS at that 
altitude and subjects with no AMS. The second cut-off value is chosen so that all AMS patients 
are identified.
An average saturation level gave negative predicative values of 0.94, 0.95, and 
0.59 in exercise tests at altitudes 3500 m, 4300 m, and 5300 m, respectively. In 
the same tests and altitudes, R-SpO
2
 provided negative predicative values of 0.91, 
0.95, and 0.66, respectively. R-SpO
2
 and Ex-SpO
2
, performed at different altitudes 
(3500-5300 m) to provide 100% sensitivity for the detection of AMS (i.e. in order 
not to miss any AMS patients before the onset of symptoms) are provided in Figure 
7. The difference between R-SpO
2
 and Ex-SpO
2
, Δ SpO
2
 at 3500 m for those subjects 
who suffered AMS was 7.4 ± 2.6 and those who did not suffer AMS 5.9 ± 3.4, ns., 
at 4300 m 7.8 ± 3.4 vs. 5.4 ± 3.1, p < 0.01 and at 5300 m 7.2 ± 2.7 vs. 7.1 ± 2.8, 
ns. respectively. Interestingly, Δ SpO
2 
at 3500 m was also greater among subjects 
who suffered AMS at 4300 m than non-AMS subjects (7.7 ± 2.9 vs. 5.5 ± 3.3, p < 
0.01) (Figure 8). At 3000 m vs. 3500 m and 4300 vs. 5300 m the difference was 
not statistically significant.
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Figure 7. SpO2 cut-off values giving 1.00 sensitivity for non-AMS for rest and exercise at different altitudes 
(3500 m, 4300 m and 5300 m). Lines for interpolating the cut-off values (“safelines”) are also 
shown. So if the climber’s measured SpO2 is above the line, he will most probably not develop 
AMS during the ascent. 
(1) Measurement based R-SpO2 when sensitivity = 1.00 and “safeline”
(2) Measurement based Ex-SpO2 when sensitivity = 1.00 and “safeline”
Figure 8. Desaturation (the difference between R-SpO2 and Ex-SpO2, Δ SpO2) was stable at different 
altitudes among those climbers who did not get AMS (right). Those climbers who did not have 
AMS at 3500 m but later at 4300 m got AMS have higher mean Δ SpO2 than those who did 
not get AMS (left) (p < 0.01). (Mean Δ SpO2, SD and range).
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3. HRV AND AMS (III)
In Study III, a total of 36 subjects were studied up to the altitude of 4300 m. 
Three discontinued because of AMS and the remaining 33 continued up to 5000 
m and 5300 m altitudes. Five made all measurements at 5600 m and one at 6300 
m altitude. The Denali 1 and Shisha expeditions reached the altitude of 5000 m 
in seven days (n=16) and the Denali 2 and Everest expeditions took 11-17 days to 
reach the same altitude (n=20) (Figure 5). Acute mountain sickness developed in 
24 out of 36 (66%) subjects at some altitude between 3000 and 5600 m, including 
both women and 22 of 34 men, while twelve men (34%) did not get AMS at any 
altitude (no-AMS group). There were 11 AMS cases in the faster group and 13 AMS 
cases in the slower group. The groups showed no difference in age, BMI or V O
2max
.
Daily ascent rates recorded here were mostly higher than the recommendations 
(300 m/day), but quite common for these mountains (range 400-1500 m). In the 
no-AMS group, RMSSD2
 min
, LF
2 min
 and HF
2 min
 increased in the first few days of 
the ascent. All HRV parameters decreased above 3500 m while HR increased.
The numbers of the AMS cases at different altitudes are presented in Table 9. 
Among those who suffered from AMS, LLS scores varied between 3 and 8. Most of 
the AMS cases occurred at 5300 m (n = 10), and the prevalence of AMS increased 
significantly with altitude and fast ascent rate on the day before the onset of AMS 
(both p < 0.001) (Figure 5). Headache and difficulty in sleeping were the most 
frequent symptoms of AMS followed by GI symptoms, fatigue, and dizziness.
At 2400 m altitude, RMSSD
2 min
 and HF
2 min
 were lower and HR higher among 
those climbers who got AMS at lower altitudes (3000-4300 m) (n=12) than in 
those who got AMS 3-7 days later at higher altitude (≥ 5000 m) (n=12) or not at 
all (n=12) (Table 9). Heart rate, lnHF
2 min
 and RMSSD
2 min
 at 2400 m correlated 
with the lowest altitude at which a climber suffered AMS (AMS altitude) (Figure 
8). There were no differences between R-SpO
2 
 at 2400 m and later onset of AMS, 
but Ex-SpO
2
 was statistically higher in the no-AMS than the AMS group at 3000-
4300 m (p < 0.01) (95% CI 3 (1-5) and in the AMS at ≥ 5000 m group (p < 0.05). 
However, Ex-SpO
2
 did not correlate with the AMS altitude (r=-0.028). At the altitude 
of 2400 m RMSSD
2
 
min
 ≤ 30 ms and Ex-SpO
2
 ≤ 91% all had 92% sensitivity for AMS 
at 3000-4300 m if ascent continued without extra acclimatization days (Figure 9). 
The sensitivity, specificity, positive and negative predicative values for chosen cut-
off values are presented in Table 10.
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no-AMS
(n=12)
AMS at 3000-
4300 m
(n=12)
AMS at ≥ 5000 m
(n=12)
HR (beats/min) 70 ± 9 82 ± 15* 62 ± 8*†
RMSSD (ms) 43 ± 25 21 ± 13* 48 ± 32†
lnLF (ms2) 7.3 ± 0.9 5.7 ± 1.1‡ 6.4 ± 0.9
lnHF (ms2) 6.1 ± 1.1 4.5 ± 1.9* 6.6 ± 1.7†
LF/HF 4.9 ± 4 6.2 ± 6 1.2 ± 1.1‡†
R-SpO2 94 ± 1 93 ± 2 94 ± 2
Ex-SpO2 91 ± 2 88 ± 3
‡ 89 ± 3*
Values are presented in mean ± SD. (*p < 0.05, ‡p < 0.01, difference between AMS 3500-4300 m vs. no-AMS groups and AMS ≥ 
5000 m vs. no-AMS groups, †p < 0.05, difference between AMS 3500-4300 m vs. AMS ≥ 5000 m). 
Table 9.  Resting heart rate (HR) and HRV parameters at 2400 m among the climbers who subsequently 
developed acute mountain sickness (AMS) at two different altitude ranges, and those who had 
no subsequent AMS.
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Figure 9. Negative correlation between HR and positive correlation between lnHF, lnLF, and RMSSD at 
2400 m altitude and the lowest altitude at which a climber got AMS (HR r = -0.743, p < 0.01; 
lnHF r=0.558, p < 0.05, lnLF r=0.302, p < 0.05, RMSSD r=0.495, p < 0.05). No-AMS subjects’ 
datapoints are added at 5600 m level (symbol ○).
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Figure 10. Scattergram showing the distribution of values of RMSSD and Ex-SpO2 measured in 24 study 
subjects at 2400 m in AMS and no-AMS. The cut-off lines RMSSD2 min ≤ 30 ms and Ex-SpO2 ≤ 
91% are for 92% sensitivity for AMS.
Sensitivity Specificity
Positive 
predicative 
value
Negative 
predicative 
value
95% 
Confidence 
Interval
RMSSD2 min ≤ 30 92% 58% 61% 83% 22(5-39)
Ex-SpO2 ≤ 91% 92% 40% 65% 80% 3(1-5)
Table 10. Sensitivity and specificity of chosen parameters at 2400 m altitude for AMS at 3000-4300 m. 
4. CASE STUDY (IV) 
Two climbers developed a severe AMS due to too rapid ascent and their denial 
of the symptoms. In the first case the patient first showed symptoms of AMS at 
3000 m altitude. The patient did not tell anyone about his symptoms. During the 
following day, the expedition continued ascend to 4800 m and the patient’s headache 
symptoms increased. Because of the headache, he started to take paracetamol (500 
mg three times a day) as pain medication. When the doctor of the expedition talked 
to him, he reported that he was well and had no symptoms of AMS at all. Next day 
at 5300 m the symptoms were so clear that he could not deny them. He had a severe 
headache, faintness, and moderately strong light-headedness which impaired his 
co-ordination and caused ataxia. His sleep the previous night had been extremely 
fragmented and he had slept only a few hours. SpO
2
 was 58% at rest, there were 
crackles and bubbling in the lung auscultation, HR was 110/min, and LLS was 6 
and later it was 8. At this moment, AMS, HAPE and HACE were diagnosed and the 
following treatment was initiated: 250 mg of acetazolamide, 20 mg of nifedipine 
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and 8 mg of dexamethasone once, and then 4 mg every eight hours. Because of 
restricted oxygen capacity, oxygen was given to him at intervals of a couple of hours 
for 20 min as adjuvant care 4 l/min. The patient’s urgent evacuation was necessary 
but since the vehicles had broken down, the evacuation was delayed. Finally he 
was transported two days later by car from 5300 m to 1500 m where the breathing 
problems resolved quickly. He still had minor ataxia and light-headedness and he 
was unable to continue the expedition. Four weeks later, the pa tient was totally 
symptom-free and healthy. 
In the second case, the climber hiked with a rucksack after 3 days acclimatization 
period from 5000 m to 5400 m altitude where the symptoms started and AMS 
developed quickly. There was a 400 m ascent to the next camp, and the distance to 
be covered was 15 km. The weather was first sunny and warm, later it was cloudy, 
and at times there was a slight snowfall. The climber drank 1900 ml of fluid during 
the trek. During the day, he excreted 500 ml of urine. On ar rival at the campsite, 
at the height of 5425 m, he was accompanied by one fellow climber. He felt a little 
tired with a slightly slowed coordination, but the camp routines went fast. After 
putting up the tent, he felt very tired and shivering cold. In the sleeping bag, his 
body temperature under the arm rose to 37.8°C. He consumed fluids in the form 
of food and drink in total 2400 ml. 
During the following night, he did not urinate at all. On falling asleep at 8:00 
p.m. his HR was 120/min and respiratory rate 30/min. After he fell asleep, his 
companion soon perceived peri odic breathing caused by high altitude which is 
similar to Cheyne-Stokes type breathing, and at 10:00 p.m., his HR rose to 130/min. 
Furthermore, the shortness of breath and the feeling of compression were found in 
the chest. The breath ing sounds were bubbling when auscultated. The SpO2 was 59%, 
LLS 8 and AMS and HAPE were diagnosed. 250 mg of Asetatzolamide and 20 mg 
of nifedipine began to be administered ev ery eight hours and the development of 
the situation was monitored during the night at intervals of 1–2 hours. The subject 
drank 600 ml of water during the night. When the symptoms eased at 2:00 a.m., 
with RR 21/min and HR 115/min, he was given permission to sleep in spite of a 
slight headache. In the morning, he was feel ing well, except for slight faintness and 
headache. He ex creted 750 ml of urine, his RR was 20/min, SpO2 71% and HR 105/
min. At lung auscultation no sounds of oedema were heard at any stage. 8 points 
on the LLS scale indicated moderate mountain sickness and the pa tient should 
have been treated with descent, oxygen or a portable hyperbaric chamber. At this 
camp, they had no oxygen treatment or evacuation facilities. They com municated 
via satphone with their travel clinic. Accord ing to the doctor’s instructions, he 
stayed at this altitude because descent was not possible. After two days’ rest, all 
symptoms disappeared, SpO2 was 74%, HR 95/min and he continued four kilometers 
on to the next camp, which was 200 m higher and had better facilities. The ascent 
went without problems and no further symptoms of AMS or HAPE occurred. The 
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medication was discontinued af ter three nights without any problems in a 5650 m 
camp when his HR was 75/min, RR 18/min and SpO2 85%. After this, the subject 
participated in the expedition nor mally without any restrictions. 
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DISCUSSION
1. OVERVIEW 
The purpose of this study was to assess the prevalence of AMS at Kilimanjaro, to 
investigate the roles of Ex-SpO
2
, R-SpO
2
, and HRV in predicting AMS during the 
expeditions, and to describe the problems of recognizing and treating AMS in the 
field. 
The most important finding in study I was that the incidence of AMS is high 
in trekkers ascending Mount Kilimanjaro. Some of the contributing factors are 
preventable, so we recommend an educational programme for all of the trekking 
agencies who guide on this peak and, in particular, the Tanzania-based guiding 
agencies which are typically driving these very fast ascent rates.
The most important finding of study II was that climbers who maintain their 
oxygen saturation at rest, and especially with exercise, most likely do not develop 
AMS. The results suggest that daily evaluation of SpO
2 
during ascent immediately 
after exertion is more indicative for a good level of acclimatization than R-SpO
2
 
alone or changes in resting HR. Ex-SpO
2
 testing can be quite easily standardized, 
even in extreme field conditions, and may prove valuable in the diagnosis and 
avoidance of AMS; however, further development of this method is required. We 
recommend that expeditions take R-SpO
2
 and Ex-SpO
2 
measurements every day 
to distinguish those who are acclimatizing well and those who may have problems 
later. Once climbers have been identified as being at risk, they can be advised by 
the leaders of teams or expeditions to take additional time to acclimatize. This 
method may enable the leaders of teams and expeditions to optimize their ascent 
rates and avoid interruptions in operations, which might otherwise be necessary 
in order to enable the rescue of climbers afflicted by altitude sickness. The safeline 
demonstrated in figure 7 needs to be tested on larger groups for different expeditions 
and altitudes in the field.
Oxygen delivery is dependent on cardiac output and CaO
2
. Within 24 hours after 
ascending to new altitude, cardiac output and HR are increased due to the hypoxia-
induced increases in sympathetic nerve activity. This increase in sympathetic nerve 
activity remains persistent even in well-acclimatized subjects (Palmer 2010). Heart 
rate and cardiac output tend to fall over several days after arrival to a new elevation. 
The decline in heart rate is of a variable degree and has been attributed to increased 
vagal input and to downregulation in the number of β-adrenergic receptors (Palmer 
2010). In study III, the elevated HR also predicts AMS in 3-5 days, and very low 
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HR at the 2400 m altitude was associated with a later onset of AMS. The HRV 
parameters had slightly better statistical power to predict AMS in the near future 
but the method for its measurement is more complex than for HR.
 As a conclusion from study III, at 2400 m decreased RMSSD
2 min
, lnLF
2 min
 and 
lnHF
2 min
 predicted AMS in a few days if the ascent continued without rest days. 
Autonomic cardiac response to increasing altitude could be a low-cost non-invasive 
test to predict impending AMS and to help distinguish those who are at risk for 
AMS and those who are acclimatizing well. The trigger values typical for impending 
AMS await further studies.
In conclusion from study IV, we can say that prevention is the safest and the most 
efficient method in the care of AMS. The symptoms may not be easily noticed, and 
thus curative measures may be delayed. Remedying the situation requires radical 
actions such as interrupting the ascent, descending, patient evacuation etc. The 
possibilities for medical treatment are limited and a portable pressure chamber 
and administering additional oxygen bring only temporary relief. Realizing the risk 
of AMS, making realistic and safe ascent plans, active elicitation of symptoms and 
timely reaction to them, in other words, discontinuing the ascent or descending, 
help to reduce and even to prevent the development of serious problems.
2. INCIDENCE OF AMS (I)
The rate of ascent is a big issue on Kilimanjaro, where several guiding agencies go 
from base to summit and back in only 6 days (Karinen et al. 2009). Despite the large 
number of studies on AMS incidence in Nepal and other areas, and despite the large 
numbers of people climbing Kilimanjaro each year, little has been published about 
AMS incidence on Kilimanjaro (McIntosh and Prescott 1986, Moore et al. 2001). 
The fast ascent rates and very high incidence of AMS are typical for this mountain. 
In study I, the prevalence and severity of AMS was assessed in a representative 
population of 112 Finnish trekkers during a climb on Mount Kilimanjaro, Tanzania. 
Interestingly, as high as 75% incidence of AMS was found in Kilimanjaro trekkers at 
Marungu Route. We consider this as a representative of groups commonly trekking 
on this peak. Although we expected a high proportion of subjects to have one or two 
high altitude related symptoms, the prevalence of AMS was surprisingly high. The 
ascent rate at Marungu Route was faster than current recommendations suggest 
(Hackett and Roach 2001, Basnyat and Murdoch 2003).
In spite of the fact that AMS, HAPE, or HACE may cause fatal symptoms, it is 
noteworthy that so many people seem to push on to the summit despite having the 
symptoms of AMS. Even though 42 (38%) subjects suffered from the symptoms of 
AMS at 2700 or 3700 m, none of them turned back. Instead, they rested a day at 
Horombo Hut and continued to climb after that. It is possible that their symptoms 
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had gone away by the time the group was ready to ascend the next morning. We 
do not have data how many of them still had AMS before continuing the ascent. 
Only three trekkers turned back from Horombo Hut, two because of high blood 
pressure and one because of mental problems (depression and loss of motivation). 
Twenty-nine (17 men and 12 women, 36%) trekkers continued the ascent to 4700 m 
even though they had AMS. Twelve of them gave up the ascent before the summit 
(8 men and 4 women). Many of the climbers had AMS in at least two different 
camps, some even more often and they should have abandoned the ascent earlier 
(Table 6). Among the Gosainkund pilgrims in the Nepal Himalayas at 4300 m, the 
incidence of HACE has been 31% (Basnyat et al 2000b). Ataxia has been mentioned 
as an early sign of impending HACE and its incidence at 4505 - 4779 m is 0.26% 
(Wu et al 2006). In study I, based on the presence of ataxia, headache, and changes 
in mental status, 6% had HACE at 3700 m, 8% at 4700 m, and 18% at 5700 m 
(table 6). Two climbers had mentioned the ataxia symptom at least two camps, or 
a day, before turning down at 5000 m, two have had the ataxia symptom at three 
camps, and two had a moderate AMS and HACE at 4700 m (LLS 7 points including 
moderate ataxia) before reaching the summit. So, they were still continuing ascent 
even though it would have been essential for them to abort the ascent immediately. 
This means that they were willing to take the greater risk of serious AMS or they 
did not know enough about altitude sickness and the risks of high altitude travel.
The different ascent rate between Kilimanjaro, and Mount Damavand and 
Annapurna area trekkers may be one reason for the different incidences of AMS. 
The Marungu Route is an extremely fast ascent to a very high altitude. This is the 
most obvious reason why the incidence rate is so high in Kilimanjaro trekkers. The 
incidence rate of AMS might be lower on other routes such as the Machame Route, 
which uses a slower ascent rate but no data was collected on this route. In this study 
population, ten climbers used acetazolamide 250 mg daily for prophylaxis. Eight of 
them got AMS. There has been a lot of discussion about the dose of acetazolamide 
in prophylactic use (Basnyat et al. 2006). Even people who took acetazolamide 
had a relatively high incidence of AMS. This suggests that even on prophylaxis, too 
rapid an ascent will cause sickness.
There were no differences in the incidence of AMS based on age or gender, a 
finding which agrees with that of previous studies (Honigman et al. 1993). Women 
seemed to descend earlier than men if they had HARS/AMS symptoms. We concur 
with the literature that the incidence of AMS increases with altitude. Similar to 
earlier reports, an abrupt increase in incidence at altitudes over 4700 m was found 
here (Maggiorini et al. 1990, Gaillard et al.2004, Ziaee et al. 2003).
Overall, the study population was comprised of mostly healthy subjects spending 
their leisure time or holiday in Africa and eager for a high altitude experience at 
the highest point of Africa. Ninety-two percent of them were normal travellers 
or hikers with no earlier experience of high altitudes or mountain climbing. This 
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population can be considered a representative cohort of the trekkers on Kilimanjaro 
because 86% completed the questionnaire. As subjects with the symptoms of AMS 
presumably tend to participate in medical studies more eagerly than those without, 
this may lead to a slight overestimation of the prevalence of AMS. On the other hand, 
we had four climbers who reached the summit with no altitude related symptoms. 
Two of them were men, aged 50 and 56 years and one woman aged 42 years. There 
may have been some underestimation of symptoms because it was their first trek 
at high altitude or because of group dynamics. One 56 year-old woman had some 
earlier altitude experiences and she reported no symptoms at all during this or 
earlier treks reaching 4000-5000 m.
Normally, the Kilimanjaro treks have a fixed timetable and for commercial 
reasons there is little opportunity to spend any extra days for acclimatisation in 
any camps. The current recommendations are to ascend only 300-600 m per day 
and to spend an acclimatization day for every 600-1200 m altitude gain (Hackett 
and Roach 2001, Basnyat and Murdoch 2003). Normal ascent rates on the Marungu 
Route are 900 m on the first day and 1080 m on the second day. On the third day 
trekkers usually rest or do a daytrip to an area 300 m higher then return to Horombo 
Hut to overnight. On the fourth day, the ascent is 940 m before the attempt on the 
summit, which is on the fifth day and the ascent rate is 970 m to Gillman’s Point or 
1180 m to Uhuru Peak (Figure 4). The main reason for the high incidence of AMS 
in Kilimanjaro seems to be rapid ascent.
It is conceivable that young hikers or males overdo things more readily and 
ignore the warning symptoms of AMS, and hence are at risk of developing a full-
blown AMS syndrome. There is evidence to suggest that certain pulmonary vascular 
abnormalities predispose to HAPE but not to AMS (Luks and Swenson 2007). 
Underlying health conditions, such as heart disease, diabetes, and hypertension, do 
not predispose to AMS (Honigman et al. 1993). In study I, there was no significant 
difference between smoking, use of acetatzolamide, the history of chronic diseases 
or asthma and others in reaching the summit or having more than 3 LLS points.
Trekkers usually have experienced guides and several well-acclimatized porters 
with them and there are no technical problems on the Marungu Route. It is easy 
to send back trekkers with AMS with the assistance of 1-2 porters. So far there 
have been no fatalities due to AMS among Finnish trekkers on Kilimanjaro, but 
the situation may change when older and greater number of trekkers want to try 
this challenge. Still, there have been numerous fatalities on this mountain among 
different nationalities indicating the need for proper education and evaluation of 
trekkers and clear instructions if AMS emerges.
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3. PREDICTION OF AMS BY SPO2 AND HRV MEASUREMENTS 
(II-III)
The diagnosis of AMS is clinical, but there are changes in physiological parameters 
before the onset of AMS. SpO
2
 at rest and during exercise at lower altitude were 
predictive of subsequent AMS at higher altitude when the ascent continued. Subjects 
susceptible to AMS had lower HRV before the clinical manifestations of AMS than 
those who acclimatized well and did not get AMS. This is a new finding and offers 
fascinating options for predicting AMS at high altitude in field conditions.
3.1. ARTERIAL O2 SATURATION (II)
Although R-SpO
2
 was of some use in distinguishing AMS patients from the non-
AMS group at 3500-5300 m, Ex-SpO
2 
was found to be a slightly better method than 
R-SpO
2
 to predict impending AMS at every altitude between 2400 m and 5300 
m. Hypoxia elicits neurohumoral and hemodynamic responses in both the brain 
and lungs, resulting in overperfusion of microvascular beds, elevated hydrostatic 
capillary pressure, capillary leakage, and consequent oedema (Hackett and Roach 
2001). On the other hand, hypoxia, exercise, and cold environment have been 
shown to increase vasoconstriction in pulmonary circulation (Gallagher and Hackett 
2004). Individuals with acute altitude sickness hypoventilate (Moore et al. 1986), 
their sympathetic activation is elevated (Mazzeo et al. 1995), and ventilatory drive 
in response to hypoxia is reduced (Barry and Pollard 2003). At sea level, both 
an excessive alveolar-to-arterial PO
2
 difference (A-a DO
2
) (> 25 to 30 torr) and 
inadequate compensatory hyperventilation (arterial PCO
2
 > 35 torr) commonly 
contribute to exercise-induced arterial hypoxemia, as do acid- and temperature-
induced shifts in O
2 
dissociation at any given arterial PO
2
. In turn, expiratory flow 
limitation may present a significant mechanical constraint to exercise hyperpnoea, 
whereas ventilation–perfusion ratio maldistribution and diffusion limitation 
contribute about equally to the excessive A-a DO
2
 (Dempsey and Wagner 1999). 
At high altitude, the hypoxemia among subjects with AMS is primarily due to an 
anatomical shunt and/or diffusion impairment and ventilation–perfusion mismatch 
(Loeppky et al. 2008). An additional factor that may possibly affect SpO
2
 at high 
altitude is extra vascular lung water accumulation and/or inflammatory changes in 
the peripheral airways (Bärtsch et al. 2002). The measurement of the SpO
2
 value 
after light exercise has been shown to be a convenient means of estimating the 
level of high altitude acclimatization among healthy subjects (Saito et al. 1995), 
and the degree of hypoxemia during exercise has been shown to correlate with the 
subsequent development of AMS at 4300 m altitude (Staab et al. 2006).
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In this study, no AMS patients were evident before 3500 m altitude, but climbers 
that experienced AMS later at higher altitudes had significantly lower SpO
2
 values 
at lower altitudes than climbers not developing AMS. For example, Ex-SpO
2
 was 
lower at 3500 m in the AMS 4300 m group than in the non-AMS group (p < 0.01). 
Thus, with Ex-SpO
2 
measurements, the first signs of impending AMS could be seen 
before any other symptoms at 3500 m in the group that developed AMS at 4300 
m (Figure 8).
In study II, a correlation was seen between SpO
2
 and AMS. The correlation was 
significantly higher between Ex-SpO
2
 and AMS than R-SpO
2
 or HR and AMS at every 
altitude examined (Table 7). There was also a weak association between R-SpO
2 
and a strong association between Ex-SpO
2 
and subsequent development of AMS. 
Monitoring SpO
2
 during exercise in addition to rest seems to improve the prediction 
of impending AMS, especially at moderate altitude (3000-3500 m). The predictive 
power of Ex-SpO
2
 was also seen at high altitude (4300-5300 m) but the difference 
between Ex-SpO
2
 and R-SpO
2
 was smaller. Desaturation level during exercise
 
had 
some predictive power at 4300 m but not at any of the other altitudes examined.
Expeditions or individual climbers may ascend faster than the recommendations 
due to the conditions of the route or climate. In study II, a method was sought for 
mountaineering expeditions to use saturation measurements at different altitudes 
to predict AMS if the ascent continues without extra acclimatization days. There 
was considerable variation in saturation levels where some climbers developed 
AMS and some did not at a given altitude. If an estimated safe saturation level 
at different altitudes is desired, the specificity of the mean saturation of the non-
AMS group is not optimal. Because the variation between saturation levels is quite 
large, it is difficult to estimate a 100% safe saturation level and too many climbers 
will be classified to the AMS risk group (see Table 8). Thus, at saturation levels 
where sensitivity to AMS is 100%, the number of those who are declared to be 
at risk but do not subsequently develop AMS is too high. This type of (“safeline”) 
approach provides an estimate of a safe saturation level during a 3500-5300 m 
expedition, which can help to identify a population that does well at altitude from 
those who may need an extra acclimatization day. Furthermore, at high altitude, 
the consequences of false positives are still minor. Those whose saturation levels 
are the lowest could be monitored more intensively or an extra acclimatization day 
could be recommended. On the other hand, approximately equal numbers of false 
positives and correct predictions were seen here when taking the mean Ex-SpO
2
 
value as a cut-off at 4300 m (see Table 8). This finding has practical consequences 
with regard to the proper planning of the ascent. Given their strong association with 
Lake Louise scores (Table 7),  man can speculate that post-exercise desaturation 
measurements have an additive value to R-SpO
2
 and they all (R-SpO
2 
, Ex SpO
2,
, Δ 
SpO
2
) represent the changing level of acclimatization and impending AMS.
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3.2. HEART RATE VARIATION (III)
In study III, a correlation was found between HRV at 2400 m and the later onset 
of AMS. The diagnosis of AMS is clinical, but some specific changes in cardiac 
autonomic function measured by HRV have been estimated to be more sensitive 
in the detection of the early signs of AMS than clinical symptoms alone at high 
altitudes (Saito et al. 2005). HRV is reported to decrease in absolute units (Kanai 
et al. 2001, Bernardi et al. 1998, Hughson et al. 1994) and LF/HF mostly increased 
when subjects got AMS (Loeppky et al. 2003, Lanfranchi et al. 2005, Chen et al. 
2008, Huang et al 2010). There are also, however, opposite findings reported about 
HRV (Koehle et al. 2010). Studies conducted in the field at high and extreme altitudes 
(> 5000 m) are still lacking.
During mild sympathetic activation, an observed increase in HR has been 
reported to be associated with an increase in LF power (Elghozi and Julien 2007). 
With more intense sympathetic stimulation, the increase in HR was associated with 
an overall decrease in HRV, including its LF component (Antila 1979, Elghozi and 
Julien 2007). Our present findings on changes in HRV values at extremely high 
altitudes support this concept.
At 2400 m, the no-AMS group had higher HRV and lower HR
2
 
min
 than the 
AMS group. The differences are not related to differences in physical fitness in the 
AMS and no-AMS groups because the basic maximum oxygen uptake did not differ 
significantly between the groups (59 ± 11 vs. 60 ± 4, p > 0.05). Furthermore, clear 
changes were not associated with the ascent. However, in the no-AMS group HF
2 
min
 tended to be lower, while LF
2 min
 tended to be higher than in the AMS group. 
The physiological significance of these findings remains uncertain but they do not 
directly support the earlier assumption that AMS is simply connected with higher 
cardiac sympathetic activity. Rather, it seems that a rise in cardiac sympathetic 
activity would have been a protective phenomenon against altitude illness. However, 
altitude illness is a dynamic process. It may be that as the AMS proceeds, HRV 
could further decrease. In other words, changes in HRV were related to higher 
altitudes in all climbers, but also notably to acclimatization and especially to failure 
to acclimatize.
The present findings are still generally in agreement with those of earlier studies 
and provide further insights on the usefulness of HRV in the prediction of AMS 
under field conditions. Several studies have shown that SpO
2 
measurements at rest 
(R-SpO
2
) and immediately after exercise (Ex-SpO
2
) are predictors of AMS (Saito 
et al. 2005, Roach et al. 1998, Burtscher et al. 2008). Our study supports this. At 
2400 m altitude the Ex-SpO
2
 was statistically higher in the no-AMS group than 
AMS 3000-4300 group (p < 0.01) and AMS ≥ 5000 m group (p < 0.05). However, 
the SpO
2 
measurements made by pulse oximetry in field conditions are susceptible 
to many disruptive factors (for example temperature, bright light, cold fingers etc.) 
(Luks and Swenson 2011). Therefore, it is desirable to have another parameter(s) 
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to follow-up for AMS susceptibility. Our findings support the possibility that HRV 
could be used along with commonly measured physiological parameters, HR and 
SpO
2,
 clinical status, and Lake Louise questionnaire for AMS prediction, in the short 
time period at moderate altitudes. The altitude of 5000 m was reached mainly 1-2 
weeks after the measurements at 2400 m and the ascent rates per day were high 
just before reaching this altitude (700-1500 m/d). This may explain better the 
high prevalence of AMS at 5000-5300 m than a predominant vagal modulation 
at rest at 2400 m.
4. TREATMENT OF AMS IN THE FIELD (IV)
Normally, lowland dwellers make their first ascents to high altitude via the easiest or 
most popular ways by using commercial tour operators. In the Himalayas, trekkers 
may take 10-15 days to reach about 5000-6000 m. The ascent of Kilimanjaro (5984 
m) usually takes five or six days. Some international airports like Lhasa or La Paz 
are even situated 3650-4058 m above sea level. Most of the tour operators have 
experienced guides with them but, for example, the business travellers may travel 
alone. It is important for all doctors and nurses who are giving health advice to 
travellers to have a basic knowledge of AMS. Patients may ask advice when planning 
a trip to highlands or mountains, or health care professionals may have to cope 
with and treat AMS on their own patients. The medicines and treatment of AMS is 
presented in Table 2 and 11 (Imray et al 2011, Basnyat and Murdoch 2003, Barry 
and Pollard 2003, Luks et al 2010).
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Mild AMS
Stop, rest and acclimatize 1-2 days, consider descent
Painkiller medicine (Paracetamol, Ibuprofen)
Antiemetics may be useful (metoclopramide)
Acetazolamide if needed
Severe AMS and/or HACE
Descent, oxygen, evacuation
Dexamethasone
Pressure bag if immediately descent is not possible 
HAPE
Descent, oxygen, evacuation
Nifedipine
Pressure bag if immediately descent is not possible 
Severe AMS that cannot type for HAPE or HACE
Descent, oxygen, evacuation
Dexamethasone
Nifedipine
Pressure bag if immediately descent is not possible
AMS – acute mountain sickness; HACE – high altitude cerebral edema; HAPE – high altitude pulmonary edema
Table 11. Treatment of altitude illness (Barry and Pollard 2003, Luks et al. 2010).
When climbing to altitudes over 3000 meters, the current recommendations 
are to ascend only 300-600 m per day and to have an acclimatization day for every 
600-1200 m of altitude gained (Imray et al. 2011, Basnyat and Murdoch 2003) so 
that the body can adapt to the altitude. In practice, travellers and climbers usually 
ascend considerably faster than the recommendation (Karinen et al. 2005). The 
slight symptoms of AMS may become more serious if the symptoms and warning 
signs are ignored. Continuing the ascent may lead to HAPE or HACE, which are life 
threatening conditions. There have been HAPE cases at 1400-2400 m even though 
these problems are usually found at altitudes over 2500 meters (Gabry et al. 2003, 
Luks et al 2010). The symptoms may increase in a few hours and the patient may 
no longer be capable of descent by himself.
During the ascent, one of the most important actions to avoid mountain 
sickness is sufficient food and drink (Butterfield et al. 1992). Lack of oxygen causes 
hyperventilation, thus dehydration while breathing increases (Milledge 1992). The 
adequate amount of fluid at high altitude is not exact but 5-7 litres of fluids per day 
are usually consumed. Often the trip is made in a different hygiene environment from 
the travellers’ country of origin and diarrhoea and vomiting may disturb the fluid and 
energy balance of the body (Milledge 1992). Lack of oxygen makes logical thinking 
more difficult, which may predispose one to serious miscalculations (Cauchy et al. 
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2002). Young healthy males are often at the greatest risk of AMS because they may 
ascend too fast too high because of their good physical condition. Physically heavy 
exertions, such as downhill skiing or climbing, are often begun before the body has 
had time to adapt to the altitude (Milledge et al. 1991). Travelling in groups gives 
extra security, but in some cases there may be an unwise competitive spirit. In the 
group, the objective analysis and reporting of the climbers’ own feelings may be 
forgotten and problems can accumulate when continuing upwards. Tight schedules 
are also dangerous. It would be good to include extra days in the schedules for rest 
and adaptation.
The denial of symptoms is common. The case studies (IV) are classic cases of 
delayed diagnosis and mismanagement of altitude illness. Two climbers developed 
a severe AMS due to too rapid ascent and their denial of the symptoms. In the first 
case, the climber first showed signs of AMS soon after leaving the 3000 m camp. 
The patient did not tell anyone about his symptoms and when asked, he denied all 
symptoms. Finally AMS was diagnosed at 5300 m altitude. Most probably he had 
got AMS 1-2 days before at 4800 altitude. The evacuation was delayed because of 
transport problems and finally he was transported two days later by car from 5300 
m to 1500 m where the breathing problems resolved quickly but he was unable to 
continue the expedition. In the second case, the climber hiked with a rucksack after 
3 days acclimatization period from 5000 m to 5400 m altitude where the symptoms 
started and AMS developed quickly. Correct reaction including the medications and 
discontinuing the ascent helped to reduce and even to prevent the development of 
serious problems. After two days’ rest, all symptoms disappeared, and he continued 
to the next camp, which was 200 m higher. The ascent went without problems and 
no further symptoms of AMS or HAPE occurred. 
Prevention is the safest and the most efficient method in the care of AMS. The 
symptoms may not be easily noticed, thus curative measures may be delayed. 
Remedying the situation requires radical actions such as interrupting the ascent, 
descending, patient evacuation etc. The opportunities for medical treatment are 
limited and a portable pressure chamber and administering additional oxygen bring 
only temporary relief (Barry and Pollard 2003, Luks et al 2010). Realizing the risk 
of AMS, making realistic and safe ascent plans, the active elicitation of symptoms 
and timely reaction to them, in other words, discontinuing the ascent or descending 
helps to reduce and even to prevent the development of serious problems.
Doctors and nurses in health centres, travel clinics and occupational health care 
clinics may be approached by patients asking advice on how to plan their trips or 
treat either themselves or a friend at high altitude, or the health care personnel 
may take part in an expedition to high altitude environment.
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5. FUTURE RECOMMENDATIONS
This study found that SpO
2
 changes a day, or a camp, before the onset of AMS. 
It is associated also with subsequent spectral changes in HRV. These provide 
sensitive parameters that will supplement the clinical estimation whether subjects 
are acclimatizing well or are at risk to suffer AMS at higher altitudes in the near 
future. Nevertheless, clinical decisions should not be based on small differences 
in SpO
2
 or HRV values over time or among individuals, but together with clinical 
status, and data from other measurements like HR and questionnaires like the 
Lake Louise questionnaire, it may help to make the right decisions in time. So the 
future recommendations are:
1. Make realistic and safe ascent plans, include in the schedules extra days for 
rest and adaptation.
2. All trekking agencies that are organising high altitude treks should have an 
educational program for their guides.
3. In the field, be active and look for symptoms of AMS and react to them in 
a timely manner.
4. Take R-SpO
2
 and Ex-SpO
2
 measurements every day to distinguish those 
who are acclimatizing well and those who may have problems later. Those 
whose saturation levels are the lowest could be monitored more intensively. 
Once climbers have been identified as being at risk, they can be advised by 
the leaders of teams or expeditions to take additional time to acclimatize.
5. Autonomic cardiac response to increasing altitude could be a low-cost non-
invasive test to predict impending AMS but the trigger values typical for 
impending AMS await further studies.
6. LIMITATIONS AND STRENGTHS
The strengths of these studies were that the rate of ascent, altitude of origin, and 
time of the day of testing could be controlled. In study II and III, in each group every 
climber also had a similar diet and physical background and they climbed the same 
route on mountains over a restricted period of time with essentially the same snow 
and weather conditions. Barometric pressure varied from day to day, but it was stable 
during individual measurements. The limitations of our study include relatively few 
data points during varying degrees of acclimatization with different rates of ascent. 
As subjects having experienced the symptoms of AMS presumably tend to participate 
in medical studies more eagerly than those without symptoms, this may lead to a 
slight overestimation of the prevalence of AMS. On the other hand, because no one 
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wants to be the weakest link in the expedition, there could be a tendency to hide 
the symptoms of AMS. There may have been some underestimation of symptoms 
because of group dynamics or the competitive spirit inside the groups. It is also 
possible to manipulate SpO
2 
values by hyperventilation, even though in the present 
study this potential source of bias was carefully controlled by the researcher. Arterial 
O
2 
and heart rate are related to the degree of acclimatization, which depends on the 
rate of ascent. Therefore, some variance in SpO
2
 measurements could be related to 
differences in rate of ascent, which is presented in Figure 5. Within the groups, the 
ascent rate was the same for all subjects. However, the exercise in Study II was not 
the same for all subjects, since a heart rate of 150 represents a different percentage 
of the maximum for each individual. In general, the ascent rate was nearly the 
same between expeditions. The camps were approximately at the same altitudes; 
three expeditions were using 11 days to reach the altitude of 5000 m and five used 
5-7 days for the same altitude. The different latitude between the Kilimanjaro, 
Himalaya, and Denali may also have some effects on the degree of acclimatization. 
The limitations of these studies include the relatively small study group at extreme 
altitude (> 5000 m). The correlations between HRV parameters and AMS are rather 
weak. Thus, further studies with larger populations are needed to verify the early 
changes in HRV between subjects with and without AMS and/or other high-altitude 
illnesses, especially at extreme altitudes, where the consequences of AMS, HACE, 
and HAPE may dramatic. The length of HRV measurements at high altitude may 
have been too short to fully observe trends of changes in HRV variables between 
subjects with and without AMS or to capture other HRV measures that could 
reflect more severe periodic breathing. The differences in ascent rates, the places 
studied, and the altitudes studied may in part explain the differences between the 
different results. Environmental and/or cardiovascular effects of previous exercise 
may have been factors in the autonomic patterns observed in subjects with AMS in 
our study. However, subjects with and without AMS were studied under the same 
field conditions and after similar recovery times as regards ascent. The ascent rates 
during the expeditions were normal and widely used in the mountains. Therefore, 
exercise and environmental factors may not explain the differences in autonomic 
cardiovascular function observed in association with AMS in this study. HRV is 
also partially influenced by respiratory rate and depth (Task Force 1996, Penttilä et al. 
2001). In the HRV frequency spectrum, power in the entire frequency area, not just the 
HF band, is also decreased if the respiration rate increases (Task Force 1996). Normally 
respiration rates will increase somewhat at high altitude, but it is unknown whether 
the respiration rate is higher in subjects with AMS than in subjects with no AMS. 
In this study, the subjects were breathing spontaneously and some of the subjects 
may have had breathing rate close to or below 0.15 Hz, being the lowest boundary 
for the HF band. For this reason, if altitude or AMS changed respiratory HRV, it 
cannot be exclusively judged by changes in HF or LF ⁄ HF. Unfortunately, sea-level 
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HRV data was not available for all subjects, so whether those climbers whose basic 
level of HF is higher could acclimatize better than those whose HF level is lower at 
sea-level could not be estimated.
Periodic breathing has been reported to exist at high altitude mainly during sleep, 
but also to some extent when awake (Insalaco et al. 1996, Fan et al. 2012). Because 
breathing frequency was not measured here, it cannot be excluded completely 
(McMullen et al. 2012). However, the visual analysis of RRI tachograms, AR 
spectrum, and Poincare plots do not support the existence of periodic breathing 
during the measurements. The measurement periods were 2 min so it can be 
assumed that any significant periodic breathing does not impact on this kind of a 
measurement period.
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CONCLUSIONS AND FUTURE PROSPECTS
In conclusion:
1. The incidence of AMS is very high among the trekkers at Mt Kilimanjaro.
2. Subjects susceptible to AMS had lower SpO
2
 at rest and especially during 
exercise before the clinical manifestations of AMS
3.  Daily measurements of SpO
2
 at rest and during exercise may help to predict 
the subsequent AMS at higher altitude if ascent continued.
4. Subjects susceptible to AMS had lower HRV before the clinical manifestations 
of AMS than those who acclimatized well and did not get AMS 2-5 days later 
if ascent continued.
5. The treatment of AMS in the field is difficult and time consuming and 
prevention is the safest and the most efficient method in the care of AMS.
Research may involve the identification of markers of susceptibility and 
incorporation of these markers into mathematical models to predict the likelihood 
that AMS will develop. Therefore, is a single or two minutes resting measurement 
reliable enough to provide a true reflection of an individual’s SpO
2
 or the balance 
of autonomic nervous system and its reactions for hypoxia and impending AMS? 
Portable devices are now available that continuously measure SpO
2
 for hours or days 
at a time. Would measurements during periods of sleep, rest, and exercise provide a 
better reflection of oxygenation and, therefore, predict AMS with greater accuracy? 
What kind of combination of portable devices and measurements at the field would 
help the clinicians or leaders of the expeditions to make correct decisions at correct 
time? Should persons with a low SpO
2
 or changes in HRV parameters take an extra 
rest day? Or could it finally mean that prophylactic drugs like acetazolamide will 
be targeted toward persons who really need them?
Clearly, there are many questions to address. However, portable pulse oximeters 
are here to stay and nearly all explorers and climbers are used to handling pulse 
meters. In the future, the practical applications of the wrist computers and HR 
monitors will increase and the analysis of HRV will become easier. Therefore, it 
is important to all those who venture to altitude to try to identify what the role of 
these devices should be.
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APPENDIX
1. AMS WORKSHEET 
Based on the Lake Louise AMS Questionnaire
Name______________________________    Age ____   Sex____  Date _____________
Treatment:
  Time   ____  ____  ____  ____  ____
  Altitude ____  ____  ____  ____  ____
1. Headache:
 No headache 0  ____  ____  ____  ____  ____
 Mild headache 1  ____  ____  ____  ____  ____
 Moderate headache 2  ____  ____  ____  ____  ____
 Severe, incapacitating 3  ____  ____  ____  ____  ____
2. GI:
 No GI symptoms 0  ____  ____  ____  ____  ____
 Poor appetite or nausea 1  ____  ____  ____  ____  ____
 Moderate nausea or vomiting 2  ____  ____  ____  ____  ____
 Severe N&V, incapacitating 3  ____  ____  ____  ____  ____
3. Fatigue/weak:
 Not tired or weak 0  ____  ____  ____  ____  ____
 Mild fatigue/weakness 1  ____  ____  ____  ____  ____
 Moderate fatigue/weakness 2  ____  ____  ____  ____  ____
 Severe F/W, incapacitating 3  ____  ____  ____  ____  ____
4. Dizzy/lightheaded:
 Not dizzy 0  ____  ____  ____  ____  ____
 Mild dizziness 1  ____  ____  ____  ____  ____
 Moderate dizziness 2  ____  ____  ____  ____  ____
 Severe, incapacitating 3  ____  ____  ____  ____  ____
5. Difficulty sleeping:
 Slept well as usual 0  ____  ____  ____  ____  ____
 Did not sleep as well as usual 1  ____  ____  ____  ____  ____
 Woke many times, poor night’s sleep 2 ____  ____  ____  ____  ____
 Could not sleep at all 3  ____  ____  ____  ____  ____
6. Change in mental status:
 No change 0  ____  ____  ____  ____  ____
 Lethargy/lassitude 1  ____  ____  ____  ____  ____
 Disoriented/confused 2  ____  ____  ____  ____  ____
 Stupor/semiconsciousness 3  ____  ____  ____  ____  ____
7. Ataxia (heel to toe walking):
 No ataxia 0  ____  ____  ____  ____  ____
 Maneuvers to maintain balance 1 ____  ____  ____  ____  ____
 Steps off line 2  ____  ____  ____  ____  ____
 Falls down 3  ____  ____  ____  ____  ____
 Can’t stand 4  ____  ____  ____  ____  ____
8. Peripheral oedema:
 No oedema 0  ____  ____  ____  ____  ____
 One location 1  ____  ____  ____  ____  ____
  Two or more locations 2  ____  ____  ____  ____  ____
Clinical Assessment Score:  ____  ____  ____  ____  ____
Total Score:  ____  ____  ____  ____  ____
